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Abstract
Chemical cross-linking and mass spectrometry (CX-MS) is a structural technique that has been gaining in
popularity with the advent of instruments that provide increased access to high-resolution MS/MS data. The
Speicher laboratory is interested in zero-length cross-links, which provide the highest-quality data, but are the
most difficult to identify and analyze. A MS sample preparation and data analysis pipeline, including a
software package called ZXMiner, has been developed to collect and analyze zero-length CX-MS data to use
in molecular modeling experiments. I used this pipeline to examine the peroxiredoxin-6 (PRDX6) enzyme,
which prevents oxidative damage in the lung. I found the identified cross-links did not fit the published crystal
structure of a catalytic intermediate, which suggests PRDX6 undergoes conformational changes as part of
catalysis. A solution structure of PRDX6 was created using this CX-MS data. Next, I performed optimization
experiments in order to adapt the ZXMiner data analysis pipeline from the LTQ Orbitrap XL instrument it
was created for to a more state-of-the-art Q Exactive Plus instrument in order to expand its ability to probe
complex samples. Combined with a new version of ZXMiner, I was able to determine several parameters that
improved the quality of cross-link data for erythrocyte membrane white ghost (WG) samples. I combined the
cross-links identified in those samples with immunoprecipitation experiments and review of the pertinent
literature to determine a topology model for the anion exchanger 1 (AE1) protein, which plays critical roles in
CO2 transport and the erythrocyte membrane skeleton. Using this topology model and published crystal
structures for the N-terminal domain of AE1, I was able to perform combinatorial modeling experiments
which resulted in a model of the full-length protein that resolved several controversies in the field. These
results show that zero-length CX-MS is a powerful technique to determine structural information of proteins
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Application  and  Refinement  of  a  Zero-­Length  Chemical  Cross-­linking  and  Mass  Spectrometry  
Method  to  Examine  Native  Protein  Structures  
Roland  F.  Rivera-­Santiago  
Dr.  David  W.  Speicher  
Chemical  cross-­linking  and  mass  spectrometry  (CX-­MS)  is  a  structural  technique  that  has  been  
gaining  in  popularity  with  the  advent  of  instruments  that  provide  increased  access  to  high-­
resolution  MS/MS  data.  The  Speicher  laboratory  is  interested  in  zero-­length  cross-­links,  which  
provide  the  highest-­quality  data,  but  are  the  most  difficult  to  identify  and  analyze.  A  MS  sample  
preparation  and  data  analysis  pipeline,  including  a  software  package  called  ZXMiner,  has  been  
developed  to  collect  and  analyze  zero-­length  CX-­MS  data  to  use  in  molecular  modeling  
experiments.  I  used  this  pipeline  to  examine  the  peroxiredoxin-­6  (PRDX6)  enzyme,  which  
prevents  oxidative  damage  in  the  lung.  I  found  the  identified  cross-­links  did  not  fit  the  published  
crystal  structure  of  a  catalytic  intermediate,  which  suggests  PRDX6  undergoes  conformational  
changes  as  part  of  catalysis.  A  solution  structure  of  PRDX6  was  created  using  this  CX-­MS  data.  
Next,  I  performed  optimization  experiments  in  order  to  adapt  the  ZXMiner  data  analysis  pipeline  
from  the  LTQ  Orbitrap  XL  instrument  it  was  created  for  to  a  more  state-­of-­the-­art  Q  Exactive  Plus  
instrument  in  order  to  expand  its  ability  to  probe  complex  samples.  Combined  with  a  new  version  
of  ZXMiner,  I  was  able  to  determine  several  parameters  that  improved  the  quality  of  cross-­link  
data  for  erythrocyte  membrane  white  ghost  (WG)  samples.  I  combined  the  cross-­links  identified  in  
those  samples  with  immunoprecipitation  experiments  and  review  of  the  pertinent  literature  to  
determine  a  topology  model  for  the  anion  exchanger  1  (AE1)  protein,  which  plays  critical  roles  in  
CO2  transport  and  the  erythrocyte  membrane  skeleton.  Using  this  topology  model  and  published  
crystal  structures  for  the  N-­terminal  domain  of  AE1,  I  was  able  to  perform  combinatorial  modeling  
experiments  which  resulted  in  a  model  of  the  full-­length  protein  that  resolved  several  
controversies  in  the  field.  These  results  show  that  zero-­length  CX-­MS  is  a  powerful  technique  to  
determine  structural  information  of  proteins  difficult  to  interrogate  through  conventional  means.  
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Chapter  1:  Introduction  
   In  this  chapter,  I  will  introduce  the  underlying  concepts  necessary  to  frame  the  
context  for  the  rest  of  this  project.  Specifically,  I  will  discuss  the  theory  behind  structural  
mass  spectrometry  and  the  literature  of  the  field  of  chemical  cross-­linking  combined  with  
mass  spectrometry.  I  will  then  focus  on  zero-­length  chemical  cross-­linking  combined  with  
mass  spectrometry,  including  the  studies  that  led  up  to  the  creation  of  the  methods  I  
used  and  optimized  as  a  member  of  the  Speicher  lab.  Most  of  the  content  in  this  chapter  
has  been  published  as  a  manuscript  in  Methods  (Rivera-­Santiago,  Sriswasdi  et  al.  
2015).  In  this  study,  Dr.  Sira  Sriswasdi  contributed  the  sections  that  describe  the  
ZXMiner  software  package,  as  well  as  the  figures  that  describe  the  effect  of  high-­
resolution  MS-­MS  spectra  and  XlinkInspector.  He  and  Ms.  Sandra  Harper  published  the  
papers  that  were  referenced  in  the  development  of  this  method.  I  then  wrote  this  
manuscript  with  input  from  the  previous  authors  and  Dr.  David  Speicher.    
1.1.  Structural  MS  
The  field  of  structural  mass  spectrometry  (MS)  uses  high-­resolution  MS  data  to  
interrogate  structural  parameters  of  complex  biological  molecules.  It  is  typically  used  as  
a  complement  to  more  established  structural  methods,  such  as  X-­ray  crystallography  
and  NMR.  Recent  studies  have  demonstrated  its  usefulness  for  proteins  and  protein  
complexes  that  were  difficult  to  examine  by  crystallography  or  NMR  (Lasker,  Forster  et  
al.  2012;;  Greber,  Boehringer  et  al.  2014;;  Olson,  Tucker  et  al.  2014;;  Sriswasdi,  Harper  et  
al.  2014;;  Belsom,  Schneider  et  al.  2015;;  Politis,  Schmidt  et  al.  2015;;  Rivera-­Santiago,  
Harper  et  al.  2015).  I  will  first  discuss  techniques  other  than  chemical  cross-­linking  
combined  with  mass  spectrometry  (CX-­MS)  then  focus  on  CX-­MS  and  advances  that  the  
2  
  
Speicher  laboratory  and  other  groups  have  made  in  this  field,  with  an  emphasis  on  
“zero-­length”  CX-­MS.  
Structural  MS  techniques  can  be  broadly  classified  as  either  top-­down  or  bottom-­
up  methods.  Top-­down  methods  derive  structural  insights  from  MS  analyses  of  intact  (or  
large  fragments  of)  proteins  and  protein  complexes.  Bottom-­up  methods  typically  involve  
MS  analyses  of  peptide  mixtures  after  proteolytic  digestion  to  identify  specific  amino  acid  
residues  that  have  been  chemically  modified  or  cross-­linked.  These  data  are  then  
translated  into  structural  information.  
For  example,  ion-­mobility  MS  (IM-­MS)  (Ruotolo,  Benesch  et  al.  2008;;  
Konijnenberg,  Butterer  et  al.  2013;;  Lanucara,  Holman  et  al.  2014)  is  a  top-­down  
technique  that  uses  the  relationships  between  the  shapes  and  sizes  of  protein  
complexes  and  their  flight  time  induced  by  an  electric  field  in  the  presence  of  a  buffer  
gas  to  provide  collisional  cross-­sections  of  protein  complexes.  These  cross-­sections  can  
then  be  used  to  distinguish  between  independently  generated  3D  structure  models.  
Some  advantages  of  IM-­MS  include  its  abilities  to  quantify  the  relative  abundance  of  
simultaneously  existing  conformations  and  to  analyze  proteins  under  native  conditions  
(Konijnenberg,  Butterer  et  al.  2013).  One  of  its  major  limitations  is  that  it  requires  stable  
transfer  of  an  intact  protein  or  protein  complex  into  the  gas-­phase  for  analysis  by  MS,  
which  is  not  always  feasible  or  efficient.  
Bottom-­up  methods  are  generally  more  flexible  than  top-­down  methods,  but  they  
suffer  from  high  sample  complexity,  challenges  in  MS/MS  data  analysis,  and  difficulty  in  
detecting  low-­abundance  modified  peptides.  Hydroxyl  radical  footprinting  (Kiselar  and  
Chance  2010;;  Wang  and  Chance  2011;;  Monroe  and  Heien  2013;;  Vahidi,  Stocks  et  al.  
3  
  
2013;;  Maleknia  and  Downard  2014;;  Yan,  Chen  et  al.  2014),  also  known  as  oxidative  
footprinting,  is  an  example  of  a  bottom-­up  technique  that  modifies  solvent-­accessible  
amino  acid  side  chains  with  hydroxyl  radicals  from  hydrogen  peroxide  or  irradiated  water  
molecules.  Changes  in  the  pattern  of  modified  residues  reflect  changes  in  protein  
surface  topology.  These  changes  can  then  be  used  to  probe  protein-­protein  and  protein-­
ligand  binding  interfaces,  or  to  infer  the  folding  process  (Poor,  Jones  et  al.  2014).  
However,  the  fact  that  almost  every  amino  acid  residue  can  be  modified  in  this  manner  
(Xu,  Takamoto  et  al.  2003;;  Xu  and  Chance  2004;;  Xu  and  Chance  2005;;  Maleknia  and  
Downard  2014)  greatly  complicates  downstream  peptide  identification.  
Hydrogen-­deuterium  exchange  (HDX)  (Wales  and  Engen  2006;;  Konermann,  Pan  
et  al.  2011;;  Wei,  Mo  et  al.  2014)  utilizes  a  similar  premise  as  oxidative  footprinting,  but  
one  key  difference  is  that  it  measures  solvent  accessibility  of  backbone  hydrogen  atoms  
via  exchanges  of  deuterium  atoms  from  deuterium-­containing  water  (D2O)  instead  of  
chemical  reactivity.  HDX  is  a  versatile  technique  that  can  be  used  as  either  a  bottom-­up  
approach  or  a  top-­down  approach  in  order  to  visualize  complex-­wide  exchange  patterns  
(Wang,  Abzalimov  et  al.  2013).  Back-­exchange,  which  is  defined  as  the  deuterated  site  
reverting  back  to  hydrogen,  is  a  major  concern  for  this  technique,  and  special  sample  
preparation  steps  coupled  with  rapid  MS  analysis  need  to  be  taken  in  order  to  ameliorate  
its  effects  (Wei,  Mo  et  al.  2014).  
1.2.  CX-­MS  
   CX-­MS  (Back,  de  Jong  et  al.  2003;;  Sinz  2006;;  Leitner,  Walzthoeni  et  al.  2010;;  
Rappsilber  2011;;  Paramelle,  Miralles  et  al.  2013)  is  a  bottom-­up  structural  MS  technique  
that  provides  information  in  the  form  of  3D  spatial  constraints  between  reactive  amino  
acid  side  chains,  which  are  tied  together  using  a  cross-­linking  reagent.  This  basic  
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concept  has  been  used  to  probe  proteins  since  the  1970s  (Fasold,  Klappenberger  et  al.  
1971),  but  the  difficulty  of  identifying  these  peptides  and  specific  cross-­linked  residues  in  
a  protein  sequence  has  severely  limited  its  use.  Interest  in  chemical  cross-­linking  has  
increased  steadily  over  the  past  decade  primarily  due  to  the  great  improvements  in  MS  
resolution  and  mass  accuracy,  which  enable  the  precise  detection  of  cross-­linked  
peptides.  The  development  of  cross-­linking  reagents  designed  specifically  for  MS  
analysis,  and  development  of  specific  data  analysis  tools  and  strategies  have  also  
contributed.  Even  large  multi-­subunit  protein  complexes  and  expansive  protein-­protein  
interaction  networks  can  be  probed  with  this  structural  MS  technique  (Chen,  Jawhari  et  
al.  2010;;  Herzog,  Kahraman  et  al.  2012;;  Lasker,  Forster  et  al.  2012;;  Leitner,  Joachimiak  
et  al.  2012;;  Walzthoeni,  Leitner  et  al.  2013).  Moreover,  applications  of  CX-­MS  are  not  
limited  to  the  use  of  the  canonical  tryptic  peptides  typical  of  bottom-­up  structural  MS  
techniques,  as  it  has  also  been  demonstrated  to  be  useful  in  the  analysis  of  intact  
proteins  (Sinz  2006).  
Most  modern  cross-­linking  reagent  designs  follow  a  basic  template  and  contain  
features  that  belong  to  four  broad  aspects:  cross-­linking  reactivity  (required),  an  
enrichment  tag  (optional),  an  isotopic  label  (optional),  and  an  MS-­cleavable  site  
(optional)  (Paramelle,  Miralles  et  al.  2013).  These  optional  features  are  typically  found  in  
the  reagent’s  spacer  arm,  which  is  a  set  of  atoms  that  is  chemically  inserted  between  the  
two  cross-­linked  amino  acid  side  chains.  The  cross-­linker’s  reactivity  is  defined  by  the  
amino  acid  side  chains  that  are  amendable  to  cross-­linking  for  a  given  chemistry.  Some  
of  the  commonly  utilized  reactivities  are  amine-­to-­amine,  carboxyl-­to-­amine,  cysteine-­to-­
cysteine,  and  cysteine-­to-­non-­specific  (photo-­activated).  Some  of  these  cross-­linkers  
also  involve  enrichment  tags  such  as  biotin  (Petrotchenko,  Serpa  et  al.  2011).  Cross-­
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linking  reagents  that  employ  isotopic  labels  are  commercially  available  as  1:1  mixtures  of  
a  single  cross-­linking  reagent  that  have  “heavy”  and  “light”  versions  of  the  spacer  arm.  
By  performing  a  cross-­linking  reaction  with  these  reagents,  all  cross-­linked  peptides  
should  have  similar  yields  of  peptide  (precursor)  ions  that  differ  in  mass  by  an  amount  
equal  to  the  mass  difference  of  the  heavy  and  light  linker  regions  (and  an  m/z  value  of  
that  mass  difference,  divided  by  the  charge).  In  an  LC-­MS/MS  experiment,  signals  
corresponding  to  cross-­linked  peptides  can  be  differentiated  from  the  uncross-­linked  
background  by  this  distinctive  heavy-­light  pattern  of  co-­eluting  peptides.  
MS-­cleavable  sites  are  labile  bonds  that  dissociate  upon  exposure  to  the  low-­
energy  fragmentation  within  the  mass  spectrometer.  These  sites  are  either  attached  to  a  
reporter  ion  as  a  marker  of  cross-­link-­specific  MS/MS  spectra  (Back,  Hartog  et  al.  2001),  
or  located  within  the  spacer  arm  of  the  cross-­linker  to  allow  the  two  peptides  forming  the  
cross-­link  to  be  separated  for  individual  MS3  analysis  (Tang,  Munske  et  al.  2005;;  Kao,  
Chiu  et  al.  2011).  However,  these  isotopic  tags  usually  requires  a  spacer  arm  of  >7Å  in  
length.  The  incorporation  of  enrichment  tags  and  MS-­cleavable  tags  make  the  cross-­
linker  spacer  arm  even  bulkier.  This  can  result  in  residues  whose  spatial  locations  in  the  
structure  of  the  protein  or  protein  complex  are  not  near  each  other  to  be  cross-­linked,  
and  therefore  greatly  reduces  the  stringency  of  the  derived  distance  constraints.  
1.3.  Structural  analysis  gaps  addressed  by  CX-­MS  
   CX-­MS  is  at  its  most  valuable  when  providing  a  basis  upon  which  to  base  a  
medium-­resolution  structural  model  that  could  not  have  been  completed  using  traditional  
structural  means.  Because  traditional  structural  biology  techniques  such  as  X-­ray  
crystallography  and  NMR  are  limited  by  the  availability  of  pure,  highly  concentrated  
protein  samples,  any  technique  that  is  capable  of  providing  structural  insights  in  the  
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event  that  obtaining  the  aforementioned  samples  is  not  possible  will  fill  some  gaps  in  the  
traditional  structural  biology  paradigm.  
   Moreover,  X-­ray  crystallography  and  NMR  tend  to  be  limited  in  terms  of  size  as  
to  what  proteins  and  protein  complexes  they  can  survey.  This  is  most  notably  the  case  
for  NMR,  as  the  spectra  get  exponentially  more  complicated  with  increased  protein  size.  
CX-­MS  does  not  have  this  size  limitation,  and  properly  designed  experiments  can  gather  
valuable  insights  about  the  conformation  of  proteins  in  close  to  an  in  vivo  setting,  as  will  
be  discussed  in  Chapter  4.  
1.4.  Zero-­length  cross-­linking  and  its  role  in  improving  structural  models  
Among  the  groups  of  cross-­linking  reagents  discussed  in  Section  1.2,  one  group  
stands  out  as  different.  Zero-­length  chemical  cross-­linkers  are  cross-­linking  reagents  
that  do  not  feature  a  spacer  arm  between  their  reactive  groups.  The  most  common  
example  of  a  zero-­length  cross-­linker  is  1-­ethyl-­3-­(-­3-­dimethylaminopropyl)  carbodiimide  
hydrochloride  (EDC).  This  cross-­linker  creates  a  highly  reactive  but  unstable  acylisourea  
with  a  short  half-­life  upon  interaction  with  a  carboxyl  amino  acid  residue  such  as  Asp,  
Glu,  or  the  C-­terminal  carboxyl  group  of  the  protein.  This  intermediate  ester  can  then  
interact  with  a  primary  amine  (Lys  or  protein  N-­terminal  amine)  to  form  a  peptidyl  bond  
with  the  elimination  of  a  water  molecule.  Ordinarily,  this  intermediate  species  has  a  
lifetime  of  several  seconds.  However,  addition  of  a  second  reagent,  N-­
hydroxysuccinimide  (NHS)  or  its  water-­soluble  sulfo-­derivative  (sulfo-­NHS),  greatly  
extends  the  lifetime  of  this  reactive  intermediate,  which  in  turn  magnifies  the  extent  of  
cross-­linking  (Staros,  Wright  et  al.  1986;;  Grabarek  and  Gergely  1990).  For  further  details  
on  the  chemistry  of  this  reaction,  please  see  Fig.  1-­1.  
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Fig.  1-­1:  Zero-­length  cross-­linking  reaction  chemistry.  Reproduced  with  permission  
from  (Rivera-­Santiago,  Sriswasdi  et  al.  2015).  (A)  Chemical  formula  for  EDC  (left)  and  
forward  cross-­linking  reaction  involving  an  acylisourea  intermediate  (right)  (B)  Chemical  
formulas  for  EDC  and  sulfo-­NHS  (left)  and  reaction  chemistry  for  zero-­length  cross-­
linking  reaction,  including:  (1)  the  reverse  reaction,  (2)  cross-­link  formation,  and  (3)  
stabilization  of  the  acylisourea  intermediate  via  substitution  for  an  amine-­reactive  sulfo-­
NHS  ester,  followed  by  cross-­link  formation.  
  

















































































































































As  was  demonstrated  via  a  systematic  in  silico  analysis  (see  Fig.  1-­2)  (Leitner,  
Walzthoeni  et  al.  2010),  zero-­length  cross-­links  provide  the  most  specific  and  powerful  
distance  constraints  for  the  refinement  and  verification  of  homology  models.  This  is  
because  zero-­length  cross-­linkers  do  not  incorporate  atoms  from  a  spacer  arm  between  
the  reactive  sites,  which  implies  that  only  residues  whose  side  chains  are  within  salt  
bridge  distance  can  interact,  and  these  shorter  distances  give  a  researcher  or  a  
structural  prediction  program  greater  resolving  power  between  potential  models.  
Fig.  1-­2:  Results  of  in  silico  analysis  of  cross-­link  distance  restraints  and  their  
effect  on  molecular  models.  Adapted  with  permission  from  (Leitner,  Walzthoeni  et  al.  
2010).  Red  line  denotes  zero-­length  cross-­linker  distance  restraints.  
  
Moreover,  because  the  reaction  can  only  occur  between  residues  that  are  
roughly  within  salt  bridge  distance  of  each  other  at  the  time  of  reaction,  any  residue  
interactions  captured  in  this  way  are  more  likely  to  describe  direct  contact  sites,  rather  
than  simply  sites  that  are  in  close  proximity  (Zybailov,  Glazko  et  al.  2013).  Zero-­length  
cross-­linking  reagents  are  also  less  likely  to  generate  “dead-­end”  products.  These  
products  occur  when  only  one  of  the  reactive  groups  is  able  to  react  with  a  site  on  a  
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protein  and  the  second  site  reacts  either  with  water  or  a  quenching  reagent.  EDC  is  less  
likely  to  produce  these  than  other  cross-­linkers,  partly  because  the  intermediate  ester  is  
relatively  unstable  and  reverts  back  to  the  unmodified  carboxyl  if  it  does  not  react  with  an  
amine.  As  a  result,  EDC  dead-­end  adducts  have  only  been  observed  at  much  high  
concentrations  of  cross-­linker  than  those  typically  used  for  zero-­length  CX-­MS  (Lopez-­
Alonso,  Diez-­Garcia  et  al.  2009).  In  contrast,  dead-­end  products  are  common  and  can  
often  have  higher  stoichiometries  than  the  actual  true  cross-­links  for  other  cross-­linking  
chemistries.  These  dead-­end  products  complicate  the  analysis  of  non-­zero-­length  cross-­
link  experiment  data  by  enlarging  the  search  space  a  database  must  consider.  Zero-­
length  cross-­link  experiments  are  also  less  likely  to  generate  “self-­linked”  products  that  
occur  when  interacting  reactive  groups  are  on  the  same  peptide  (Zybailov,  Glazko  et  al.  
2013),  as  both  reactive  groups  would  have  to  be  on  the  same  digestion  enzyme  peptide  
and  also  directly  interact  in  a  salt  bridge  for  that  to  happen.  Dead-­end  and  self-­linked  
products  of  non-­zero-­length  cross-­linkers  are  problematic  because  they  must  be  
accounted  for  in  database  searches.  
The  major  challenge  with  zero-­length  cross-­linkers  for  CX-­MS  experiments  is  
how  difficult  it  is  to  identify  these  sub-­stoichiometric  cross-­linked  peptides  in  the  
presence  of  the  far  more  numerous  and  more  abundant  linear  peptides.  This  is  because  
adding  MS-­cleavable  bonds  to  generate  MS3  fragmentation  spectra  (Kao,  Chiu  et  al.  
2011)  or  direct  incorporation  of  differential  isotopic  labels  as  part  of  the  cross-­linking  
reaction  are  not  feasible,  as  discussed  above.  However,  there  is  an  alternative  isotopic  
labeling  method  can  be  used  with  zero-­length  cross-­linkers.  It  involves  tagging  the  N-­  or  
C-­termini  of  peptides  following  the  cross-­linking  reaction,  which  helps  distinguish  cross-­
linked  peptides  as  they  contain  two  N-­  or  C-­termini  instead  of  one  each  (El-­Shafey,  Tolic  
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et  al.  2006).  Unfortunately,  with  the  exception  of  strategies  that  introduce  an  isotopic  tag  
during  proteolysis,  such  as  18O  (Back,  Notenboom  et  al.  2002),  interpretation  of  N-­  or  C-­
terminal  tags  can  be  complicated  by  the  presence  of  internal  reactive  groups  in  linear  
peptides.  
Another  challenge  with  zero-­length  CX-­MS,  which  also  applies  to  its  non-­zero-­
length  counterparts,  is  that  the  number  of  possible  cross-­links  increases  exponentially  
with  the  amount  of  unique  sequences  in  the  target  protein  or  protein  complex,  potentially  
making  the  search  space  unmanageably  large  (Leitner,  Walzthoeni  et  al.  2010).  For  the  
purposes  of  database  search  space,  the  limiting  factor  is  the  amount  of  unique  primary  
sequence,  rather  than  the  molecular  weight  of  the  total  protein  complex.  This  sequence  
complexity  problem  is  particularly  challenging  for  zero-­length  cross-­linking  experiments.  
This  is  due  in  large  part  to  the  absence  of  an  MS-­based  method  to  differentiate  between  
modified  and  unmodified  peptides.  
As  with  most  other  types  of  cross-­linkers,  the  specificity  of  zero-­length  cross-­
linkers  (such  as  EDC)  is  a  double-­edged  sword.  Because  its  cross-­linking  reaction  only  
involves  lysine,  aspartic  acid,  glutamic  acid  residues,  and  unmodified  protein  termini,  
EDC  cannot  be  used  to  interrogate  regions  that  lack  any  of  these  residues.  Furthermore,  
the  reactive  groups  themselves  need  to  be  accessible  in  aqueous  solution.  Hence,  any  
reactive  groups  that  are  buried  within  a  protein  or  macromolecular  complex,  or  buried  
within  the  lipid  bilayer  will  be  refractory  to  cross-­linking.  Additionally,  very  large  and  very  
hydrophobic  cross-­linked  peptides  are  generally  very  difficult  to  detect  in  a  mass  
spectrometer  tuned  for  peptide  analysis.  Therefore,  regions  of  protein  that  contain  
reactive  sites  but  no  conveniently  located  proteolytic  sites  will  be  difficult  to  interrogate  
by  CX-­MS,  although  use  of  an  alternative  protease  may  minimize  this  problem.  
11  
  
1.5.  Other  groups’  efforts  
   Due  in  large  part  to  the  disadvantages  mentioned  above,  zero-­length  CX-­MS  has  
typically  been  a  low-­usage  technique  in  the  CX-­MS  field.  In  fact,  I  surveyed  a  series  of  
CX-­MS  reviews  published  since  2012,  and  I  saw  that  zero-­length  CX-­MS  was  either  not  
mentioned  (Hyung  and  Ruotolo  2012;;  Serpa,  Parker  et  al.  2012;;  Stengel,  Aebersold  et  
al.  2012;;  Merkley,  Cort  et  al.  2013;;  Walzthoeni,  Leitner  et  al.  2013;;  Budayeva  and  
Cristea  2014)  or  only  superficially  discussed  (Pacholarz,  Garlish  et  al.  2012;;  Paramelle,  
Miralles  et  al.  2013).  Despite  all  of  these  caveats,  several  studies  by  other  groups  have  
productively  utilized  zero-­length  CX-­MS  in  various  capacities.  
One  of  these  studies  took  a  qualitative  approach  to  zero-­length  CX-­MS  by  
utilizing  it  as  a  low-­impact  stabilizing  reagent  for  protein  macrocomplexes,  which  were  
then  analyzed  by  matrix-­assisted  laser  desorption  ionization  (MALDI)  time  of  flight  
(TOF)-­MS  (Lepvrier,  Doigneaux  et  al.  2014).  This  study  did  not  identify  specific  cross-­
linked  peptides.  It  instead  used  cross-­linking  to  stabilize  quarternary  protein  complexes  
of  up  to  388  kDa  in  size,  which  contained  around  126.6  kDa  in  unique  protein  sequence.  
Another  study  combined  MALDI-­TOF  MS  with  zero-­length  cross-­linking  in  an  
effort  to  gain  insights  on  the  interactions  composing  the  photosystem  II  (PSII)  in  green  
algae  (Nagao,  Suzuki  et  al.  2010).  This  study  found  that  the  proteins  known  as  PsbO,  
PsbP,  and  PsbQ  form  close  interactions  with  each  other,  as  well  as  with  several  other  
proteins  in  PSII.  Additionally,  an  interaction  between  PsbP’s  N-­terminus  and  PsbQ’s  C-­




Several  studies  focused  on  mapping  protein-­protein  interactions  and  used  zero-­
length  cross-­links  to  determine  the  precise  interaction  sites  between  two  purified  proteins  
known  to  associate  with  each  other  (Schmidt,  Kalkhof  et  al.  2005;;  Marekov  2007;;  
Bumpus  and  Hollenberg  2010).  One  study  focused  on  the  interaction  between  the  
cytochrome  P450  2B6  enzyme  and  NADPH-­cytochrome  P450  reductase  (Bumpus  and  
Hollenberg  2010).  This  study  used  18O  labeling  and  de  novo  MS/MS  sequencing  to  
identify  and  analyze  cross-­links  between  a  synthetic  peptide  mimicking  the  C-­helix  of  
cytochrome  P450  2B6  and  the  connecting  domain  of  the  76.7  kDa  P450  reductase.  
Another  study  used  Fourier  transform  ion  cyclotron  resonance  (FT-­ICR)  MS  
analysis  to  probe  the  interface  between  calmodulin  and  adenylyl  cyclase  8  (Schmidt,  
Kalkhof  et  al.  2005).  A  similar  technique  with  a  variety  of  cross-­linkers,  including  EDC,  
was  later  used  to  map  the  interaction  between  calmodulin  and  the  skeletal  muscle  
myosin  light  chain  kinase  M13  (Kalkhof,  Ihling  et  al.  2005).  The  resulting  cross-­links  
were  manually  identified  with  the  aid  of  the  General  Protein  Mass  Analysis  for  Windows  
(GPMAW)  (Peri,  Steen  et  al.  2001)  and  the  Automatic  Spectrum  Assignment  Program  
(ASAP)  (Young,  Tang  et  al.  2000)  software  packages,  along  with  manual  verification.  
These  cross-­links  revealed  an  interaction  between  a  26-­residue  peptide  corresponding  
to  the  N-­terminus  of  M13  and  the  EF-­hand  2  domain  in  calmodulin,  which  is  in  
agreement  with  an  NMR  structure  of  the  complex.  
Zero-­length  CX-­MS  was  also  utilized  in  combination  with  data  from  other  structural  
techniques  to  assist  homology  modeling  of  the  interaction  interface  between  proteins.  
One  such  study  explored  the  interface  between  cytochrome  P450  2E1  and  cytochrome  
b5  using  FT-­ICR  MS,  and  was  able  to  generate  a  model  of  the  interaction  surface  of  the  
roughly  70kDa  1:1  complex  (Gao,  Doneanu  et  al.  2006).  In  another  study,  the  binding  
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interface  of  the  transiently  PSII-­associated  protein  known  as  Psb27  was  probed  via  zero-­
length  CX-­MS  (Liu,  Huang  et  al.  2011),  and  the  resulting  cross-­links  were  identified  
using  MassMatrix  (Xu  and  Freitas  2009).  This  experiment  showed  that  Psb27  associates  
with  the  chlorophyll  binding  protein  CP43  at  two  distinct  sites,  and  a  model  of  for  the  61  
kDa  complex  (with  61  kDa  of  unique  sequence)  was  constructed.  An  interesting  study  
combined  HDX  and  zero-­length  CX-­MS  to  re-­examine  the  dimerization  interface  of  the  
14-­3-­3ζ  protein  (Haladova,  Mrazek  et  al.  2012).  These  analyses  uncovered  novel  
contacts  in  the  56kDa  dimer  interface  and  resolved  ambiguous  salt  bridge  interactions  
that  were  previously  noted.  
Several  groups  have  attempted  to  improve  zero-­length  CX-­MS  data  analysis  and  
to  reduce  the  reliance  on  manual  verification.  One  study  proposed  a  program,  named  
Popitam.  Popitam  was  based  on  the  premise  that  a  fragmentation  pattern  of  a  zero-­
length  cross-­linked  peptide  can  be  approximated  as  a  mixture  of  two  peptides,  each  
having  a  modification  of  unknown  size  (corresponding  to  the  other  peptide)  attached.  
This  allows  the  MS/MS  spectra  of  cross-­linked  peptides  to  be  semi-­automatically  
annotated  via  conventional  peptide  identification  schemes  (Singh,  Shaffer  et  al.  2008).  
The  algorithm  was  tested  on  a  model  system  of  the  cytochrome  P450  2E1-­cytochrome  
b5  complex.  A  later  study  by  the  same  group  employed  this  protocol  as  part  of  a  de  novo  
protein  modeling  experiment  in  conjunction  with  previously  published  cryo-­EM  data  in  
order  to  determine  the  structure  of  the  roughly  20  kDa  gpE  viral  capsid  protein  for  
bacteriophage  lambda  (Singh,  Nakatani  et  al.  2013).  Another  zero-­length  CX-­MS  
analysis  strategy  modified  the  database  search  algorithm  of  a  popular  MS  data  analysis  
software  package,  known  as  SEQUEST  (Eng,  McCormack  et  al.  1994).  This  modified  
algorithm  considered  all  possible  products  from  a  cross-­linking  reaction  and  the  
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subsequent  tryptic  digest  (cross-­linked  peptides,  adducts,  and  linear  peptides),  
generated  theoretical  spectra,  then  matched  them  to  the  observed  spectra  (McIlwain,  
Draghicescu  et  al.  2010).    
As  the  above  studies  illustrate,  applications  of  zero-­length  CX-­MS  were  mostly  
limited  to  fairly  small  proteins  or  protein  complexes  because  of  the  limitations  in  
detection  capacity  for  zero-­length  cross-­links.  Many  of  these  studies  also  either  relied  on  
prior  knowledge  of  the  interaction  interace  or  reported  protein-­protein  interactions  
without  identifying  specifically  cross-­linked  residues.  Those  that  did  identify  specific  
cross-­linked  residues  typically  involved  extensive  manual  analysis  of  MS/MS  spectra,  
which  make  the  data  analysis  tedious  and  unfeasible.    
1.6.  The  Speicher  laboratory’s  initial  enhancements  to  zero-­length  CX-­MS  
   The  Speicher  laboratory  also  performed  several  early  zero-­length  CX-­MS  studies  
of  red  cell  spectrin.  These  were  done  using  recombinant  protein  constructs  that  
preserved  functionally  important  interfaces  instead  of  the  full-­length  protein.  Initially,  a  
combination  of  the  SEQUEST  (Eng,  McCormack  et  al.  1994),  GPMAW  (Peri,  Steen  et  al.  
2001),  and  ASAP  (Young,  Tang  et  al.  2000)  software  packages,  along  with  extensive  
manual  curation  of  MS/MS  spectra,  was  used  to  develop  a  structure  for  the  spectrin  
heterodimer  initiation  site.  The  recombinant  proteins  used  here  were  approximately  100  
kDa  in  size,  with  an  equivalent  amount  of  unique  protein  sequence  (Li,  Tang  et  al.  2008).  
A  subsequent  study  utilized  Rosetta  Elucidator  (Rosetta  Biosoftware,  Seattle,  
WA),  GPMAW  (Peri,  Steen  et  al.  2001),  and  the  homology  modeling  program  
MODELLER  (Sali  and  Blundell  1993)  to  determine  a  model  of  the  spectrin  
tetramerization  interface  using  a  “mini-­spectrin”  recombinant  construct.  This  construct  
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formed  a  180  kDa  “tetramer”  complex  with  90  kDa  of  unique  sequence  (Li,  Harper  et  al.  
2010).  
While  these  studies  resulted  in  useful  structural  insights,  similar  limitations  to  the  
above  studies  by  other  groups  were  encountered.  As  mentioned  above,  the  data  
analysis  methods  used  were  tedious  and  time-­consuming,  and  the  number  of  high-­
confidence  cross-­links  identified  was  modest.  These  limitations  led  to  the  development  
of  a  new  data  analysis  pipeline  specifically  tailored  for  zero-­length  CX-­MS  analysis,  
which  is  described  in  below.  
1.7.  Development  of  ZXMiner  and  multi-­stage  MS  analysis  of  zero-­length  CX-­MS  
peptides  
   Because  zero-­length  cross-­linkers  do  not  possess  any  of  the  special  properties  
discussed  above  that  can  aid  in  cross-­linked  peptide  identification,  the  Speicher  
laboratory  developed  an  LC-­MS/MS  data  analysis  method  coupled  with  an  open-­source  
software  tool  named  Zero-­Length  Cross-­link  Miner  (ZXMiner).  The  data  acquisition  
method  and  the  software  were  specifically  optimized  for  identification  of  zero-­length  
cross-­links.  
There  are  two  key  components  to  this  strategy  (see  Fig.  1-­3).  First,  parallel  LC-­
MS/MS  analyses  of  a  cross-­linked  sample  and  an  otherwise  identical  uncross-­linked  
control  are  performed,  and  a  label-­free  comparison  of  the  resulting  LC-­MS  datasets  is  
performed  to  identify  putative  cross-­linked  precursors.  This  process  was  developed  for  
use  with  LTQ-­Orbitrap  XL  mass  spectrometers  (Thermo  Scientific,  Waltham,  MA),  which  
can  conduct  MS  scans  in  the  high-­resolution  orbitrap  and  MS/MS  scans  in  the  low-­
resolution  ion  trap  in  parallel  to  achieve  a  high  duty  cycle.  However,  the  duty  cycle  was  
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too  low  when  MS/MS  scans  were  also  conducted  in  the  orbitrap  in  order  to  obtain  high  
resolution,  high  mass  accuracy  MS/MS  data  in  unbiased  discovery  runs.  This  approach  
resulted  in  very  few  identified  cross-­linked  peptides.  
Fig.  1-­3:  Diagram  for  the  zero-­length  CX-­MS  cross-­linking  protocol,  as  optimized  
for  a  LTQ  Orbitrap  MS  instrument.  Reproduced  with  permission  from  (Rivera-­
Santiago,  Sriswasdi  et  al.  2015).  The  protocol  is  separated  into  3  major  categories:  
sample  preparation,  label-­free  LC-­MS  comparison,  and  comparison  to  all  possible  
theoretical  cross-­linked  peptides  (in  yellow),  database  search  of  candidate  spectra  and  
cross-­link  identification  (in  red),  and  incorporation  of  distance  restraints  into  homology  




In  order  to  counteract  this  problem,  the  Speicher  laboratory  employed  a  two-­
tiered  MS  analysis  approach  (Li,  Harper  et  al.  2010;;  Harper,  Sriswasdi  et  al.  2013;;  
Sriswasdi,  Harper  et  al.  2014;;  Sriswasdi,  Harper  et  al.  2014).  Specifically,  as  shown  in  
Fig.  1-­3,  the  initial  comparison  of  the  control  and  cross-­linked  is  achieved  by  a  “discovery  
run”.  This  is  defined  as  a  high-­speed,  low-­resolution  acquisition  run  of  MS/MS  data  in  the  
ion  trap.  This  is  followed  by  a  “targeted  run”  with  low-­speed,  high-­resolution  acquisition  
of  MS/MS  data  in  the  orbitrap.  This  two-­step  procedure  required  additional  LC-­MS/MS  
runs  for  most  experiments,  but  it  allowed  acquisition  of  high-­resolution  MS/MS  data  for  
all  putative  cross-­linked  peptides  without  compromising  the  method’s  depth  of  analysis.  
Some  key  details  of  the  method  and  representative  results  are  described  below.  
   In  an  ideal  cross-­linking  experiment,  each  molecule  of  protein  or  protein  complex  
should  contain  only  one,  or  at  most  a  few,  cross-­links  in  order  to  minimize  the  risk  of  
over-­cross-­linking  and  altering  the  native  structures  of  interest.  Because  of  this,  cross-­
linked  peptides  typically  constitute  much  less  than  1%  of  the  peptides  in  a  tryptic  digest  
of  a  cross-­linked  sample.  Because  uncross-­linked  control  samples  should  contain  all  
detectable  linear  peptides,  a  quantitative  label-­free  comparison  of  LC-­MS  patterns  of  a  
control  and  cross-­linked  sample  can  be  used  to  remove  these  peptides  from  further  
consideration.  In  an  earlier  study  [ref],  a  10-­fold  intensity  enrichment  (cross-­link  to  
control)  cutoff  was  used  to  compensate  for  the  limited  ability  of  the  Elucidator  software  
that  was  being  used  by  the  Speicher  laboratory  at  that  time  to  distinguish  isotopic  
envelope  patterns  of  low-­intensity  cross-­linked  precursors  from  overlapping  noise.  
To  overcome  this  limitation,  the  Speicher  laboratory  developed  a  label-­free  
comparison  software  module  for  ZXMiner  whose  purpose  was  determine  the  correct  
precursor  masses  and  charge  states  of  all  ions  and  aligned  two  LC-­MS  patterns  
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(manuscript  in  preparation).  This  module  operates  under  similar  concepts  to  those  
utilized  by  the  proteome  analysis  software  known  as  MaxQuant  (Sriswasdi,  Harper  et  al.  
2014).  Namely,  it  used  the  correlation  of  intensity  profiles  across  LC-­MS  scans  to  
improve  the  detection  and  de-­convolving  of  isotopic  envelopes  into  monoisotopic  
species  prior  to  performing  label-­free  comparisons.  This  is  a  critical  improvement  when  
compared  to  Elucidator,  which  matches  discrete  MS  signals  regardless  of  whether  they  
are  part  of  a  peptide  isotopic  envelope.  The  current  label-­free  comparison  module  
greatly  diminishes  random  matches  between  cross-­linked  peptide  signals  and  spurious  
signals  in  the  control  sample,  as  illustrated  in  Table  1-­1.  This  increases  the  specificity  of  
label-­free  comparison,  and  greatly  decreases  the  number  of  candidate  cross-­linked  
peptides  for  subsequent  targeted  high-­resolution  MS/MS  analyses.  
Table  1-­1:  Distinguishing  Interference  in  Control  Samples  Using  Label-­Free  
Comparison  Software.  Reproduced  with  permission  from  (Sriswasdi,  Harper  et  al.  
2014).  







1   3   819.0875   YEEHLY[E]R-­{MSPILGYW[K]IK   1.9e+05   Absent  
1   4   614.5674   YEEHLY[E]R-­{MSPILGYW[K]IK   3.7e+05   Absent  
1#   5   495.0544   YEEHLY[E]R-­{M#SPILGYW[K]IK   4.7e+03   Absent  
2   4   877.9311   FELGLEFPNLPYYIDG[D]VK-­HNMLGGCP[K]ER   3.6e+05   Absent  
2#   3   1175.5707   FELGLEFPNLPYYIDG[D]VK-­HNM#LGGCP[K]ER   9.3e+04   Absent  
3   4   970.4894   HNMLGGCP[K]ER-­NKKFELGLEFPNLPYYIDG[D]VK   5.1e+04   Absent  
3#   4   974.4881   HNM#LGGCP[K]ER-­NKKFELGLEFPNLPYYIDG[D]VK   2.9e+04   Absent  
4   3   1212.9374   KFELGLEFPNLPYYIDG[D]VK-­HNMLGGCP[K]ER   6.2e+04   Absent  
4   4   909.9549   KFELGLEFPNLPYYIDG[D]VK-­HNMLGGCP[K]ER   4.3e+05   Absent  
4#   3   1218.2691   KFELGLEFPNLPYYIDG[D]VK-­HNM#LGGCP[K]ER   5.7e+04   Absent  
4#   4   913.9536   KFELGLEFPNLPYYIDG[D]VK-­HNM#LGGCP[K]ER   1.7e+04   Absent  
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5   3   854.4874   LLL[E]YLEEK-­IEAIPQID[K]YLK   1.4e+04   Absent  
5   4   641.1174   LLL[E]YLEEK-­IEAIPQID[K]YLK   Absent   6.05e+06  a  
6   4   680.1426   LLL[E]YLEEK-­RIEAIPQID[K]YLK   7.0e+03   Absent  
7   3   912.1363   LLLEYLE[E]K-­YIAD[K]HNMLGGCPK   Absent   Absent  
7#   3   917.4679   LLLEYLE[E]K-­YIAD[K]HNM#LGGCPK   1.0e+04   Absent  
7#   4   688.3527   LLLEYLE[E]K-­YIAD[K]HNM#LGGCPK   4.3e+04   Absent  
8   3   683.3577   [D]F[E]TLK-­IAYS[K]DFETLK   1.1e+05   Absent  
8   4   512.7701   [D]F[E]TLK-­IAYS[K]DFETLK   1.2e+05   Absent  
9   5   664.5565   YIAWPLQGWQATFGGG[D]HPPK-­I[K]GLVQPTR   1.9e+04   Absent  
10   4   464.7658   LLL[E]YLEEK-­YL[K]SSK   Absent   Absent  
11   3   1023.5399   LP[E]MLK-­[K]FELGLEFPNLPYYIDGDVK   1.1e+05   Absent  
11#   3   1028.8716   LP[E]M#LK-­[K]FELGLEFPNLPYYIDGDVK   2.3e+05   Absent  
12   3   1248.3078   YIAWPLQGWQATFGGGDHPP[K]}-­V[D]FLSKLPEMLK   1.2e+05   Absent  
13   3   1012.5001   MFE[D]R-­[K]FELGLEFPNLPYYIDGDVK   1.7e+05   Absent  
a  Further  inspection  confirms  that  a  precursor  with  similar  m/z  and  charge  state  is  present  in  the  control  
sample.  The  intensity  level  of  this  precursor  was  16  times  lower  than  that  of  the  cross-­link  sample  and  did  
not  trigger  an  MS/MS  scan.  Elucidator  could  not  detect  this  precursor.  
   The  capability  of  modern  mass  spectrometers  to  produce  high-­resolution,  high-­
mass-­accuracy  MS  data  has  been  instrumental  in  advancing  the  field  of  proteomics.  
Until  recently,  acquisition  of  high-­resolution  MS/MS  spectra  was  less  common  (Frank,  
Savitski  et  al.  2007;;  Pan,  Park  et  al.  2010).  To  identify  linear  peptides,  low-­resolution  
MS/MS  spectra  with  mass  accuracy  of  about  ±  0.5  Da,  such  as  those  obtained  in  a  linear  
ion  trap,  were  reasonably  adequate  for  common  search  engines  such  as  SEQUEST  
(Eng,  McCormack  et  al.  1994),  MASCOT  (Perkins,  Pappin  et  al.  1999),  etc.  
However,  because  cross-­linked  peptides  are  much  larger  and  typically  feature  
higher  charge  states  than  their  linear  counterparts,  their  MS/MS  spectra  are  much  more  
complex.  Multiple  fragmented  ions,  often  with  different  charge  states,  will  frequently  
occur  within  a  ±  0.5  Da  mass  tolerance  window  with  substantial  frequency.  Furthermore,  
the  combinatorial  expansion  in  search  space  when  considering  cross-­linked  samples  
from  n  peptides  to  the  order  of  n2  cross-­linked  peptides  dramatically  increases  the  
frequency  where  different  theoretical  cross-­linked  peptides  having  precursor  masses  
within  5-­10  ppm  of  one  another  by  chance.  Because  of  these  factors,  low-­resolution  
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MS/MS  spectra  can  be  relatively  ineffective  at  distinguishing  between  alternative  cross-­
linked  peptide  assignments  (see  Fig.  1-­4).  
Fig.  1-­4:  High-­resolution  MS/MS  spectra  are  required  for  high-­confidence  
identification  of  cross-­linked  peptides.  Reproduced  with  permission  from  (Rivera-­
Santiago,  Sriswasdi  et  al.  2015).  In  a  zero-­length  cross-­linking  study  of  a  large  526  kDa  
spectrin  heterodimer  using  an  Orbitrap  XL  mass  spectrometer,  a  typical  MS/MS  scan  
can  be  matched  to  as  many  as  97  distinct  theoretical  cross-­linked  peptides  within  a  10-­
ppm  mass  tolerance  range.  The  red  X  highlights  the  correct  assignment.  The  geometric  
mean  (GM)  score  (Sriswasdi,  Harper  et  al.  2014)  represents  the  quality  of  a  match  
between  a  cross-­link  sequence  and  an  MS/MS  spectrum.  (A)  Analysis  of  low-­resolution  
MS/MS  data  cannot  distinguish  between  the  97  alternative  theoretical  cross-­linked  
peptides.  (B)  With  high-­resolution  MS/MS  data,  only  a  single  correct  assignment  stands  
out  with  a  non-­zero  score.  
  
  










































The  ZXMiner  data  acquisition  strategy  overcomes  the  aforementioned  drop  in  
duty  cycle  that  occurs  on  hybrid  ion  trap  instruments  when  MS/MS  scans  are  acquired  at  
high  resolution  by  acquiring  LC-­MS/MS  data  in  two  stages.  LC-­MS  data  from  the  
discovery  analyses  was  subjected  to  the  label-­free  comparisons  described  above  and  
the  low-­resolution  MS/MS  associated  with  putative  cross-­linked  spectra  were  evaluated  
using  ZXMiner  (Sriswasdi,  Harper  et  al.  2014)  with  low  stringency  scoring  parameters.  
These  two  analyses  significantly  narrow  down  the  list  of  candidate  cross-­linked  peptide  
precursors.  As  a  result,  only  a  few  parallel  targeted  LC-­MS/MS  runs  were  needed  to  
obtain  high-­resolution,  high-­accuracy  MS/MS  spectra  for  all  candidate  precursors.  
In  these  targeted  analyses,  both  MS  and  MS/MS  scans  were  conducted  in  the  
Orbitrap  and  for  complex  samples,  lists  of  candidates  were  split  among  multiple  LC-­
MS/MS  runs  to  ensure  several  attempted  MS/MS  analyses  of  all  targeted  peptides  
across  each  chromatographic  peak.  The  number  of  runs  required  can  be  estimated  by  
plotting  the  expected  number  of  target  precursors  during  each  chromatographic  time  
interval  (the  precursor  retention  times  are  extracted  from  the  discovery  runs).  The  
minimum  signal  threshold  for  triggering  an  MS/MS  scan  was  set  at  30,000  ion  counts  (as  
compare  to  the  typical  setting  of  1,000  ion  counts  to  trigger  MS/MS  scans  in  the  ion  trap)  
to  compensate  for  the  reduced  sensitivity  of  the  orbitrap  mass  analyzer.  Additionally,  the  
monoisotopic  precursor  selection  option  was  turned  on,  and  precursors  with  charge  
states  of  +1  and  +2  were  screened  out,  as  they  would  rarely  correspond  to  cross-­linked  
tryptic  peptides.    
   The  most  critical  component  in  the  development  of  an  optimized  zero-­length  
cross-­linking  analysis  pipeline  was  the  creation  of  ZXMiner.  This  software  tool  was  
developed  to  address  three  major  goals:  increase  the  throughput  of  zero-­length  cross-­
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linking  experiments  by  automating  data  analysis,  increase  the  number  of  assigned  
cross-­links,  and  improve  the  confidence  of  cross-­link  assignments.  The  Speicher  
laboratory  tested  ZXMiner  against  other  cross-­linked  peptide  analysis  software.  Only  one  
previously  developed  cross-­link  analysis  software  package,  pLink  (Yang,  Wu  et  al.  
2012),  could  utilize  high-­resolution  MS/MS  data  effectively.  Additionally,  none  of  the  
software  packages  that  had  been  previously  utilized  in  zero-­length  CX-­MS  studies  were  
capable  of  interpreting  the  aforementioned  data  in  a  high-­mass  accuracy,  high-­
throughput  fashion,  which  is  what  prompted  development  of  ZXMiner.  A  direct  
comparison  shows  that  ZXMiner  significantly  outperforms  pLink  (Zhu,  Smith  et  al.  2010),  
StavroX  (Gotze,  Pettelkau  et  al.  2012),  Crux  (Park,  Klammer  et  al.  2008),  and  
MassMatrix  (Xu  and  Freitas  2009)  when  used  for  zero-­length  cross-­link  detection,  as  
shown  in  Table  1-­2.  The  data  for  the  true  positives  as  compared  to  the  false  positives  
(assigned  by  comparison  to  the  crystal  structure)  suggests  that  the  maximum  distance  
cutoff  that  can  be  expected  for  an  EDC  cross-­link  is  roughly  16Å.  Another  interesting  
observation  is  that  the  the  actual  false  discovery  rate  (FDR)  is  typically  much  higher  than  
an  estimated  FDR  for  all  methods  when  tested  on  standard  proteins.  It  is  also  
noteworthy  that  at  the  unique  sequence  level,  ZXMiner  could  identify  the  largest  number  
of  true  cross-­links  with  no  false  positives.  
Table  1-­2:  Comparison  of  GST  crosslink  identifications  using  alternative  software.  
Reproduced  with  permission  from  (Sriswasdi,  Harper  et  al.  2014).  For  each  peptide  
sequence,  charge  states  of  the  cross-­linked  peptide  identified  by  each  software  package  
are  indicated.  Estimated  false  discovery  rates  (FDRs)  were  derived  from  the  decoy  data  
that  each  software  package  provided  (not  available  from  MassMatrix).  Number  of  
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Peptide  Sequence   Cα-­Cα  Distance   ZXMiner   pLink   StavroX   Crux
a   Mass  Matrixb  
True  Positives  
1   YEEHLYER-­{MSPILGYWKIK   5.5   3,4   3,4,5   3   3,4,5   3,4   5  
1#   YEEHLYER-­{M#SPILGYWKIK   5.5   5   4,5   -­   3,4   N/A   5  
2   FELGLEFPNLPYYIDGDVK-­HNMLGGCPKER   8.7   4   4   -­   -­   3,4   4  
2#   FELGLEFPNLPYYIDGDVK-­HNM#LGGCPKER   8.7   3   3   -­   -­   N/A   3  
3   HNMLGGCPKER-­NKKFELGLEFPNLPYYIDGDVK   8.7   4   4,5   -­   -­   4,5   4  
3#   HNM#LGGCPKER-­NKKFELGLEFPNLPYYIDGDVK   8.7   4   4   -­   -­   N/A   5  
4   KFELGLEFPNLPYYIDGDVK-­HNMLGGCPKER   8.7   3,4   3,4   -­   -­   3,4   3  
4#   KFELGLEFPNLPYYIDGDVK-­HNM#LGGCPKER   8.7   3,4   3,4   -­   -­   N/A   5  
5   LLLEYLEEK-­IEAIPQIDKYLK   9.2   3,4   3,4   3   3,4   3,4   -­  
6   LLLEYLEEK-­RIEAIPQIDKYLK   9.2   4   4   -­   4   -­   -­  
7   YEEHLYER-­{M#SPILGYWK   10.0   -­   -­   -­   3,4   N/A   N/A  
8   LLLEYLEEK-­YIADKHNMLGGCPK   11.4   3   3   3   -­   3   3  
8#   LLLEYLEEK-­YIADKHNM#LGGCPK   11.4   3,4   3,4   -­   -­   N/A   -­  
9   DFETLK-­IAYSKDFETLK   11.6   3,4   3,4   3   3   3,4   -­  
10   YIAWPLQGWQATFGGGDHPPK}-­IKGLVQPTR   11.8   5   5   -­   5   5   5  
11   LPEMLK-­KFELGLEFPNLPYYIDGDVK   12.4   3   3,4   -­   3,4   3,4   3  
11#   LPEM#LK-­KFELGLEFPNLPYYIDGDVK   12.4   3   3   -­   4   N/A   4  
12   LLLEYLEEK-­YLKSSK   12.4   4   4   -­   3,4   4   -­  
13   AEISMLEGAVLDIRYGVSR-­YIADKHNM#LGGCPK   13.8
c   -­   -­   -­   -­   N/A   4  
14   YIAWPLQGWQATFGGGDHPPK}-­VDFLSKLPEMLK   14.6
d   -­   5   5   -­   4,5   5  
14#   YIAWPLQGWQATFGGGDHPPK}-­VDFLSKLPEM#LK   14.6
d   3   3   -­   3,4   N/A   5  
15   MFEDR-­KFELGLEFPNLPYYIDGDVK   15.8c,d   3   3   3   -­   -­   -­  
15#   M#FEDR-­KFELGLEFPNLPYYIDGDVK   15.8c,d   -­   -­   -­   3   N/A   3  
  
False  Positives  
1   LLLEYLEEK-­LVCFKK   16.3   -­   -­   -­   -­   3   -­  
2   IKGLVQPTR-­DEGDK   16.4   -­   -­   3   4   3   -­  
3   IKGLVQPTR-­DEGDKWR   16.4   -­   -­   -­   3   -­   -­  
4   DEGDKWR-­LPEMLK   18.5   -­   -­   -­   3,4   3   -­  
5   DEGDKWRNK-­LPEMLKMFEDR   18.5   -­   -­   -­   -­   3   -­  
6   VDFLSKLPEMLKMFEDR-­ER   19.0   -­   -­   -­   -­   -­   3  
6#   VDFLSKLPEMLKM#FEDR-­ER   19.0   -­   -­   -­   3   N/A   -­  
7   IKGLVQPTR-­LLLEYLEEK   19.1   -­   -­   -­   -­   -­   3  
8   {MSPILGYWKIK-­ERAEISMLEGAVLDIR   20.9   -­   -­   -­   4   -­   -­  
9   ERAEISMLEGAVLDIRYGVSR-­WRNKK   21.5   -­   -­   -­   -­   3   -­  
10   IKGLVQPTR-­DFETLK   22.7   -­   3   3   -­   3   3  
11   HNMLGGCPKER-­LVCFKK   23.9   -­   -­   -­   -­   3   -­  
12   LLLEYLEEK-­DEGDKWR   25.2   -­   3   -­   3   -­   -­  
13   YEEHLYERDEGDKWR-­AEISM#LEGAVLDIR   27.2   -­   -­   -­   -­   N/A   4  
14   VDFLSKLPEMLKMFEDR-­YIADKHNMLGGCPK   28.5   -­   -­   -­   -­   5   -­  
15   IEAIPQIDKYLK-­MFEDR   29.6   -­   -­   3   -­   -­   -­  
16   LLLEYLEEK-­LPEMLKMFEDRLCHK   33.4   -­   -­   -­   -­   3   -­  
17   DFETLK-­LVCFKK   34.2   -­   -­   -­   3   -­   -­  
   Estimated  FDR:   <  1%   <  5%   <  5%   <  5%   <  5%   N/A  
Unique  Precursor  Level   True  Positives:   25   30   6   20   19   15  
   False  Positives:   0   2   3   8   9   4  
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   Actual  FDR:   0%   6.3%   33%   29%   32%   21%  
Unique  Sequence  Level   True  Positives:   13   15   6   10   11   10  
   False  Positives:   0   2   3   7   9   4  
   Actual  FDR:   0%   12%   33%   41%   45%   29%  
a  Crux’s  default  setting  cannot  identify  peptides  with  variable  modifications.  
b  MassMatrix  cannot  identify  cross-­links  involving  the  protein  terminus  as  one  of  the  cross-­linked  
sites.  
c  Cross-­links  between  subunits.  
d  Cross-­links  involving  flexible  regions  (as  reflected  by  the  elevated  B-­factors  and/or  loops).  
   ZXMiner  accepts  input  MS  data  in  mzXML  format,  along  with  a  list  of  candidate  
MS/MS  scans  generated  by  a  label-­free  comparison  tool,  and  databases  of  pertinent  
protein  sequences  in  FASTA  format.  The  software  first  performs  an  in  silico  digestion  of  
the  proteins  with  the  specified  enzyme  (usually  trypsin),  which  is  then  followed  by  
production  of  a  list  of  all  possible  theoretical  cross-­linked  peptides.  The  masses  of  these  
theoretical  cross-­linked  peptides  are  calculated  as  the  sum  of  the  theoretical  peptide  
masses  after  accounting  for  the  mass  change  caused  by  a  cross-­linking  reaction,  which  
is  defined  by  the  user.  These  masses  are  then  compared  to  those  of  the  candidate  
cross-­linked  peptide  precursors,  resulting  in  matches  between  theoretical  cross-­link  
sequences  and  candidate  MS/MS  spectra.  As  the  LC-­MS  data  was  obtained  at  high  
mass  accuracy,  a  stringent  mass  tolerance,  typically  5  or  10  ppm,  is  applied  here.  For  
each  match,  ZXMiner  processes  the  MS/MS  spectrum,  performs  an  in  silico  
fragmentation  of  the  putative  cross-­link  sequence  to  generate  a  list  of  theoretical  MS/MS  
ions,  and  calculates  “coverage”  scores  that  represent  how  well  the  two  sets  of  data  
overlap.  Individual  scores,  as  well  as  their  geometric  mean  (GM),  which  is  an  overall  
indicator  of  cross-­link  match  quality,  are  reported.  When  analyzing  high-­resolution  
MS/MS  spectra,  ZXMiner  de-­convolutes  all  isotopic  envelopes  and  collapses  them  into  
monoisotopic  peaks.  This  use  of  de-­convoluted  high-­resolution  MS/MS  data  is  a  critical  
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factor  that  helps  ZXMiner  outperform  other  software  packages  and  achieve  a  low  false  
discovery  rate  (FDR)  without  sacrificing  cross-­link  coverage,  as  previously  shown  
(Sriswasdi,  Harper  et  al.  2014)  (see  Table  1-­2).  
   Another  important  feature  of  ZXMiner  is  that  it  creates  intermediate  files  
throughout  a  run’s  progression  that  record  the  output  of  its  raw  search  results  and  
subsequent  interpretation.  These  files  can  contain  the  scores  of  all  evaluated  MS/MS  
spectra,  cross-­linked  peptides,  and  even  alternative  cross-­linked  sites  on  each  peptide.  
Hence,  users  can  re-­specify  search  parameters  such  as  minimum  peptide  length,  
minimum  scores,  or  precursor  mass  tolerance  and  use  ZXMiner  to  rapidly  recalculate  
the  FDR  for  each  identified  cross-­link  without  having  to  re-­process  LC-­MS/MS  and  
sequence  data.  XlinkInspector,  which  is  part  of  the  ZXMiner  package,  can  be  used  to  
inspect  the  quality  of  each  identified  cross-­link  and  confirm  the  exact  cross-­linked  site  
(see  Fig.  1-­5).  In  recognition  that  frequently  only  a  few  weak  MS/MS  ions  distinguish  
between  alternative  cross-­linked  sites  within  a  peptide,  the  final  decision  regarding  
alternative  cross-­link  site  assignments  is  left  to  the  user,  instead  of  simply  having  
ZXMiner  output  the  highest-­scoring  candidates.  
Fig.  1-­5:  XlinkInspector  is  a  graphical  interface  within  ZXMiner  that  aids  
verification  of  cross-­linked  peptide  assignment  and  determination  of  cross-­linked  
sites.  Reproduced  with  permission  from  (Rivera-­Santiago,  Sriswasdi  et  al.  2015).  (A)  
The  tabbed  interface  allows  quick  navigation  between  individual  cross-­link  assignments  
for  visual  inspection  of  data  quality.  (B)  The  header  displays  basic  information  about  the  
selected  MS/MS  spectrum.  (C)  This  more  detailed  interface  provides  flexibility  for  
spectrum  annotation  and  plotting.  (D)  The  list  of  identified  fragmented  ions  can  be  
exported  for  further  inspection.  The  annotated  spectrum  can  also  be  exported  in  
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publication-­ready  Scalable  Vector  Graphics  format  (SVG).  (E)  Visual  representation  of  
the  identified  b-­  and  y-­ions  on  the  two  peptide  sequences.  The  assigned  cross-­linked  
residues  are  highlighted  in  red.  (F)  Color-­coded  plot  of  MS/MS  data.  Identified  major  b-­  
and  y-­ions  are  shown  in  green.  Neutral  losses  are  shown  in  blue.  Precursor-­related  ions  
are  shown  in  red.  Yellow  and  pink  cutoff  lines  indicate  minimum  intensity  values  required  
to  be  designated  as  a  peak  or  scored  in  the  GM  scoring  algorithm,  respectively.  (G)  
Alternative  cross-­linked  sites  are  listed  along  with  their  respective  coverage  scores.  
Annotation  of  the  MS/MS  spectrum  dynamically  changes  in  panel  F  when  different  
cross-­link  sites  are  selected  in  panel  G.  
  
1.8.  Previous  studies  done  by  the  Speicher  laboratory  using  ZXMiner  
   The  Speicher  laboratory  has  employed  ZXMiner  and  zero-­length  CX-­MS  in  
several  projects.  The  most  common  use  of  these  zero-­length  CX-­MS  IDs  are  to  uncover  










proteins  and  protein  complexes.  For  this  latter  application,  high  confidence  cross-­link  
assignments  from  ZXMiner  are  then  applied  as  distance  constraints  to  molecular  
modeling  programs,  such  as  MODELLER  (Sali  and  Blundell  1993).  The  distance  
constraint  utilized  for  such  experiments  is  typically  tied  to  the  location  of  the  α-­carbon  
atoms  of  the  cross-­linked  residues.  The  reason  why  the  Speicher  laboratory  chose  this  
as  the  restriction  method  is  because  the  α-­carbon  backbone  of  a  protein  usually  provides  
more  reliable  information  for  the  purposes  of  model-­building.  This  distance  restraint  is  
typically  set  at  12Å,  but  the  Speicher  laboratory  has  reported  observing  distances  of  up  
to  16Å  for  high-­confidence  cross-­links  in  areas  likely  to  exhibit  conformational  flexibility  
when  evaluating  ZXMiner  on  solved  crystal  structures  (Sriswasdi,  Harper  et  al.  2014).  
This  upper  boundary  is  further  illustrated  in  Fig.  1-­6,  which  also  highlights  the  importance  
of  having  high-­mass  accuracy  MS/MS  spectra.  The  most  notable  studies  employing  
ZXMiner  aimed  to  elucidate  structural  insights  for  human  red  cell  spectrin  tetramers,  as  
well  as  large  conformational  differences  between  “closed”  dimers  and  “open”  dimers  
(Sriswasdi,  Harper  et  al.  2014).  A  90  kDa  fused  heterodimer  construct  with  the  intact  
tetramerization  site  was  used  as  a  simplified  surrogate  for  the  full-­sized  526  kDa  
heterodimer  for  these  zero-­length  CX-­MS  experiments  (Harper,  Li  et  al.  2010).  CX-­MS  
analysis  of  mini-­spectrin  tetramers  using  ZXMiner  revealed  important  additional  cross-­
links  not  previously  identified  using  older  data  acquisition  and  data  analysis  methods  (Li,  
Tang  et  al.  2008;;  Li,  Harper  et  al.  2010),  which  enabled  determination  of  a  more  refined  
structure  for  the  spectrin  tetramer  region  (see  Fig.  1-­7).  
Fig.  1-­6.  Analysis  of  GST  cross-­links  using  ZXMiner.  Reproduced  with  permission  
from  (Sriswasdi,  Harper  et  al.  2014).  (A)  Locations  of  identified  cross-­links  on  the  crystal  
structure  of  the  GST  homodimer  (PDB  ID:  1GTA).  Lys  residues  are  highlighted  in  blue  
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and  Glu  and  Asp  are  in  red.  The  black  lines  connect  the  two  α-­carbons  of  each  cross-­
link.  Cross-­links  between  residues  whose  Cα-­Cα  distances  are  significantly  larger  than  
12  Å  were  highlighted  in  orange.  (B)  Scatter  plot  showing  the  relationship  between  GM  
scores  derived  from  high-­resolution  MS/MS  data  and  Cα-­Cα  distances  for  all  cross-­
linked  peptide  candidates  in  the  GST  data  set.  A  few  cross-­links  located  in  regions  likely  
to  exhibit  increased  flexibility,  such  as  loops  or  inter-­subunit  interfaces,  slightly  exceeded  
the  expected  12  Å  maximum  Cα-­Cα  distance.  (C)  ROC  curves  showing  the  superior  
performance  of  high-­resolution  MS/MS  data  (area  under  the  curve  =  0.99)  compared  
with  low-­resolution  data  (area  under  the  curve  =  0.80).  
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Fig.  1-­7.  Structures  for  mini-­spectrin  tetramer  based  on  zero-­length  CX-­MS  data  
analysis  using  ZXMiner.  Reproduced  with  permission  from  (Sriswasdi,  Harper  et  al.  
2014).  (A)  Locations  of  inter-­domain  cross-­links  used  to  model  mini-­spectrin  tetramer.  
Blue  lines  indicate  cross-­links  identified  previously  (Li,  Harper  et  al.  2010);;  red  lines  
indicate  new  cross-­links  identified  using  the  ZXMiner  workflow;;  dashed  lines  indicate  the  
same  cross-­links  repeated  in  the  second  half  of  the  tetramer.  (B)  Superimposition  of  
present  and  previous  tetramer  structures.  (C)  Space-­filling  representations  of  tetramer  
models.  β-­spectrin  domains  are  colored  in  bright  or  pale  cyan,  and  α-­spectrin  domains  
are  colored  in  bright  or  pale  orange  to  distinguish  the  two  strands.  
  
Analysis  of  mini-­spectrin  dimers  revealed  several  distance  constraints  that  were  
mutually  exclusive  and  were  produced  by  the  open  and  closed  dimer  forms  of  the  protein  
that  were  in  equilibrium  and  could  not  be  independently  isolated.  Distance  constraints  
derived  from  these  cross-­links  allowed  the  Speicher  laboratory  to  generate  the  first  
structures  for  the  open  and  closed  forms  of  mini-­spectrin  dimers  (see  Fig.  1-­8)  
(Sriswasdi,  Harper  et  al.  2014).  
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Fig.  1-­8.  Zero-­Length  CX-­MS  enables  identification  and  modeling  of  large  changes  
in  conformation  for  mini-­spectrin  dimers.  Reproduced  with  permission  from  
(Sriswasdi,  Harper  et  al.  2014).  (A)  Open  dimer-­specific  cross-­links  indicative  of  
nonhelical  connectors  before  (left)  and  after  (right)  structural  refinement.  Lys  residues  in  
blue;;  Glu/Asp  residues  in  red;;  green  lines  are  cross-­links  with  labeled  Cα–Cα  distances.  
(B)  Open  dimer  model  supported  by  two  cross-­links  between  α0  and  α1  domains.  (C)  
Structures  showing  the  interconversion  between  fully  extended  open  dimer  to  closed  
dimer.  
  
Moreover,  subsequent  studies  utilizing  an  L207P  mutant  of  the  mini-­spectrin  
construct,  which  is  a  mutation  previously  shown  to  destabilize  tetramer  formation  and  
which  causes  hereditary  elliptocytosis  in  patients  with  this  mutation  (Gallagher,  Tse  et  al.  
1992),  revealed  cross-­links  outside  the  expected  ranges  of  molecular  flexibility  of  the  
wild-­type  mini-­spectrin  dimer.  Distance  constraints  derived  from  these  cross-­links  were  
used  to  elucidate  a  structure  of  the  mutant  dimer  (see  Fig.  1-­9),  which  in  turn  illustrated  
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the  allosteric  effects  of  this  mutation.  Similar  studies  were  also  conducted  on  an  L260P  
mutant  that  has  similar  destabilizing  effects  on  spectrin  tetramer  formation  (Glele-­Kakai,  
Garbarz  et  al.  1996),  revealing  a  similar  structural  perturbation  to  that  shown  in  Fig.  1-­9  
(Harper,  Sriswasdi  et  al.  2013).  
Fig.  1-­9.  Cross-­links  and  structure  for  the  L207P  mutant  mini-­spectrin  dimer.  
Reproduced  with  permission  from  (Sriswasdi,  Harper  et  al.  2014).  (A)  Locations  of  
αL207P  inter-­domain  cross-­links;;  the  asterisk  indicates  the  location  of  the  αL207P  
mutation.  (B)  Locations  of  five  αL207P  mutant-­specific  cross-­links  indicative  of  
conformational  rearrangements  in  the  α1-­α2-­α3  region  plotted  on  the  WT  structure  for  
comparison;;  blue,  Lys;;  red,  Glu/Asp;;  black,  Pro  mutation;;  black  lines,  cross-­links  with  
Cα–Cα  distances  labeled.  (C)  Model  of  the  αL207P  mutant  closed  dimer.  (D)  Cα–Cα  
distances  for  inter-­domain  cross-­links  identified  in  the  αL207P  mutant  dimer  on  the  WT  
and  αL207P  closed  dimer  structures.  (E)  Superimposition  of  α2  domains  from  the  WT  





   In  summary,  CX-­MS  is  an  emerging  structural  technique  that  is  taking  advantage  
of  the  recent  technological  advances  in  MS/MS  instrumentation  and  software.  Zero-­
length  cross-­links  offer  the  best  quality  of  data  it  provides  for  generating  and  validating  
structural  models,  but  these  pose  significant  challenges  in  terms  of  detection  and  
analysis.  The  Speicher  laboratory  is  particularly  interested  in  zero-­length  CX-­MS,  and  
has  recently  developed  a  powerful  method  to  systematically  analyze  these  samples  in  
ZXMiner  (Sriswasdi,  Harper  et  al.  2014).  This  program  has  already  been  employed  in  
several  structural  studies  involving  spectrin  constructs,  and  it  has  proven  to  dramatically  
enhance  the  modeling  that  can  be  performed  using  zero-­length  CX-­MS  as  a  validation  
mechanism.  This  means  that  zero-­length  CX-­MS  combined  with  molecular  modeling  is  
an  approach  that  has  great  potential  for  further  advancement  and  improvement,  as  I  will  










Chapter  2:  Solution  structure  of  biologically  active  human  peroxiredoxin-­6  
   In  this  chapter,  I  will  describe  a  collaborative  project  I  undertook  with  other  
members  of  the  Speicher  laboratory,  as  well  as  members  of  Dr.  Aron  Fisher’s  laboratory  
in  the  University  of  Pennsylvania.  Most  of  the  content  in  this  chapter  has  been  published  
as  a  manuscript  in  The  Biochemical  Journal  (Rivera-­Santiago,  Harper  et  al.  2015).  In  this  
study,  Dr.  Suiping  Zhou  and  Dr.  Sheldon  Feinstein  prepared  the  recombinant  protein,  
Ms.  Sandra  Harper  cross-­linked  the  protein,  and  I  performed  the  LC-­MS  analysis  and  the  
homology  modeling  experiments.  I  then  wrote  the  manuscript  with  inputs  from  all  the  
authors,  as  well  as  from  Dr.  Aron  Fisher  and  Dr.  David  Speicher.  
2.1.  Background  
One  major  project  I  embarked  upon  once  I  had  a  grasp  of  ZXMiner  and  its  
requisite  skills  was  to  collaborate  with  Dr.  Aron  Fisher’s  group  in  determining  the  solution  
structure  of  peroxiredoxin-­6.  Our  interest  in  the  protein  was  driven  by  its  role  in  
regulation  of  oxidative  stress  in  human  lungs,  because  the  presence  of  reactive  oxygen  
species  (ROS)  and  their  by-­products  can  have  multiple  deleterious  effects  on  cells.  The  
lung  is  particularly  vulnerable  to  these  effects,  due  to  its  continual  exposure  to  oxidants  
via  ambient  air  as  well  as  its  extensive  capillary  networks  (Fisher,  Forman  et  al.  1984).  
Oxidative  damage  has  been  notably  associated  with  various  disease  states  in  the  lung,  
ranging  from  acute  lung  injury  (ALI)  to  chronic  obstructive  pulmonary  disease  (COPD)  
(Lang,  McArdle  et  al.  2002;;  Rahman  and  Adcock  2006).  
In  order  to  protect  against  oxidative  injury,  eukaryotic  cells  express  a  number  of  
anti-­oxidative  stress  proteins.  Among  these  is  a  family  of  proteins  known  as  
peroxiredoxins.  Peroxiredoxins  differ  from  others  involved  in  similar  functions  by  working  
in  conjunction  with  thiol-­containing  electron  donor  molecules,  as  opposed  to  using  redox  
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cofactors  or  prosthetic  groups  (Wood,  Schroder  et  al.  2003;;  Rhee,  Chae  et  al.  2005).  
Most  peroxiredoxins  employ  two  conserved  Cys  residues  in  a  disulfide  bond  as  their  
electron  donor  group  in  the  presence  of  a  reductant,  typically  thioredoxin.  This  is  known  
as  a  2-­Cys  mechanism  (Wood,  Schroder  et  al.  2003;;  Rhee,  Chae  et  al.  2005).  
Peroxiredoxin-­6  (PRDX6)  is  a  unique  case  in  the  peroxiredoxin  family.  It  is  a  
homo-­dimeric  enzyme  found  in  mammals,  particularly  mammalian  lungs  (Manevich  and  
Fisher  2005),  and  it  features  at  least  two  distinct  enzymatic  activities  –  the  reducing  
property  common  to  all  peroxiredoxins,  as  well  as  phospholipase  A2  (PLA2)  via  a  
conserved  catalytic  triad  (His-­26,  Ser-­32,  Asp-­140)  (Kang,  Baines  et  al.  1998;;  Manevich,  
Reddy  et  al.  2007).  It  is  also  the  only  peroxiredoxin  with  the  reported  ability  to  reduce  
phospholipid  hydroperoxides  (Fisher,  Dodia  et  al.  1999).  Moreover,  PRDX6  does  not  
feature  the  two  canonical  Cys  residues  that  are  characteristic  of  most  members  of  the  
peroxiredoxin  family.  For  PRDX6,  one  cysteine  residue,  Cys-­47,  is  conserved  across  
species.  Thus,  its  peroxidase  activity  is  described  as  a  1-­Cys  mechanism  that  involves  
oxidation  of  Cys-­47  to  a  sulfenic  acid  as  a  peroxidase  catalytic  intermediate.  The  
enzymatic  cycle  is  completed  by  reduction  of  the  active  site  back  to  a  sulfhydryl  by  
glutathione  in  conjunction  with  glutathione  S-­transferase  (Chen,  Dodia  et  al.  2000;;  Ralat,  
Manevich  et  al.  2006).  PRDX6’s  PLA2  activity  is  regulated  by  phosphorylation  of  a  Thr-­
177  residue,  indicating  that  activation  of  the  PLA2  activity  involves  a  conformational  
change  (Wu,  Feinstein  et  al.  2009;;  Rahaman,  Zhou  et  al.  2012).  Both  the  PLA2  as  well  
as  the  phospholipid  hydroperoxide  activities  require  conformational  specificity  in  the  
binding  of  the  enzyme  to  the  phospholipid  substrate  (Manevich,  Shuvaeva  et  al.  2009).  
A  high-­resolution  crystal  structure  for  human  PRDX6  has  already  been  solved  
(PDB  ID:  1PRX),  but  several  alterations  were  made  to  the  base  protein  in  order  to  obtain  
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it.  Most  notably,  it  was  apparently  necessary  to  mutate  a  non-­conserved  cysteine  (Cys-­
91)  and  oxidize  the  active  site  cysteine  to  the  sulfenic  form  in  order  get  diffraction-­quality  
crystals  (see  Fig.  2-­1)  (Rhee,  Chae  et  al.  2005).  Because  the  active  site  is  in  the  
catalytic  intermediate  state  (active  site  sulfenic  acid),  the  crystal  structure  does  not  seem  
to  completely  reflect  the  solution  structure  of  the  reduced  form  of  the  protein.  For  
example,  a  recent  study  showed  that  Thr-­177,  which  is  totally  buried  in  the  crystal  
structure,  can  be  phosphorylated,  indicating  solvent  exposure  under  conditions  that  
should  include  the  conformation  in  solution  of  the  protein  with  Cys-­47  in  the  reduced  
state  (Wu,  Feinstein  et  al.  2009;;  Rahaman,  Zhou  et  al.  2012).  This  phosphorylation  
induces  a  further  conformational  change  that  increases  PLA2  activity  and  affinity  for  
liposomes.  Other  biochemical  data  indicate  that  the  protein  undergoes  conformational  
changes  that  can  modulate  enzyme  activity,  such  as  the  conformational  change  that  
results  in  protein  activation  when  binding  with  glutathione-­S-­transferase  (GST)  (Ralat,  
Manevich  et  al.  2006)  and  the  one  that  occurs  upon  binding  to  the  phospholipid  head  
group  (Manevich,  Reddy  et  al.  2007).  Considering  the  substantial  conformational  
flexibility  of  the  protein  and  importance  of  conformational  changes  on  both  enzyme  








Fig.  2-­1.  Crystal  structure  of  human  PRDX6  (PDB  ID:  1PRX).  Reproduced  with  
permission  from  (Rivera-­Santiago,  Harper  et  al.  2015).  Subunit  A  in  blue;;  Subunit  B  in  
cyan.  (A)  Cartoon  representation  of  the  dimer.  Cys-­47  in  yellow  sticks;;  Cys-­91  in  orange  
sticks.  (B)  Solid  surface  representation  of  the  dimer.  Phospholipase  catalytic  triad  (Ser-­









2.2.1.  Expression,  purification,  and  validation  of  recombinant  PRDX6  
   As  noted  above,  I  received  cross-­linked  PRDX6  samples  that  had  been  
expressed  and  purified  by  the  Fisher  lab  using  a  previously  published  protocol  (Chen,  
Dodia  et  al.  2000;;  Manevich  and  Fisher  2005;;  Manevich,  Reddy  et  al.  2007).  These  
samples  had  also  been  validated  by  Ms.  Harper  before  they  were  cross-­linked,  using  
size  exclusion  chromatography  as  well  as  sedimentation  equilibrium  experiments.  She  
found  that  PRDX6  existed  in  a  strong  dimeric  form  in  solution  and  it  was  in  the  reduced  
state,  which  was  according  to  expectations  (Rivera-­Santiago,  Harper  et  al.  2015)  (see  
Fig.  2-­2).  
Fig.  2-­2.  Oligomer  states  and  conformations  of  human  PRDX6  protein  
preparations.  Reproduced  with  permission  from  (Rivera-­Santiago,  Harper  et  al.  2015).  
Experiments  performed  by  Ms.  Sandra  Harper.  (A)  HPLC  gel  filtration  of  recombinant  
human  PRDX6.  (B)  Sedimentation  equilibrium  of  the  human  PRDX6  peak  at  three  
different  initial  loading  concentrations  (0.8  mg/ml  in  black,  0.4  mg/ml  in  red,  and  0.2  
mg/ml  in  green)  at  26,200  rpm  and  30  °C.  All  samples  were  prepared  and  analyzed  in  20  




2.2.2.  CX-­MS  analysis  of  PRDX6  
Cross-­linked  PRDX6  samples  for  different  temperatures  (0°C  and  37°C),  gel  
bands  corresponding  to  different  oligomeric  states  (monomer  vs.  dimer),  and  different  
cross-­linking  reagents  (EDC/NHS,  DSG,  DSS)  were  generated  (see  Fig.  2-­3).  Cross-­
linker  concentrations  for  reactions  at  0°C  for  EDC  and  sulfo-­NHS  were  20  mM  and  10  
mM,  respectively,  whereas  they  were  2.5  mM  and  1.25  mM,  respectively,  at  37°C.  In  the  
case  of  DSG  and  DSS,  concentrations  were  1  mM  at  0°C,  and  0.125  mM  at  37°C.  This  
adjustment  was  done  in  order  to  account  for  increased  molecular  activity  at  higher  
temperatures.  
Fig.  2-­3.  Chemical  cross-­linking  of  the  codon  optimized  human  PRDX6.  
Reproduced  with  permission  from  (Rivera-­Santiago,  Harper  et  al.  2015).  Experiments  
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performed  by  Ms.  Sandra  Harper.  SDS-­PAGE  of  the  human  PRDX6  after  incubation  with  
the  indicated  chemical  cross-­linkers.  Control  (C)  and  time  points  (minutes)  are  indicated  
above  each  lane.  The  position  of  molecular  weight  markers  are  shown  on  the  left,  and  
the  migration  of  monomer  and  dimer  bands  are  indicated.  
  
The  SDS-­PAGE  and  trypsin  digestion  methods  have  been  previously  described  
(Sriswasdi,  Harper  et  al.  2014).  Briefly,  samples  for  the  reactions  described  above  were  
run  in  SDS-­PAGE  gels  and  bands  of  interest  were  excised  and  digested  with  trypsin.  
2.2.3.  LC-­MS  analysis  of  EDC  cross-­linked  samples  
For  identification  of  zero-­length  cross-­links,  the  cross-­linked  and  control  human  
PRDX6  tryptic  digests  were  analyzed  and  cross-­linked  sites  were  identified  as  previously  
described  using  an  LTQ-­Orbitrap  XLTM  mass  spectrometer  (Thermo  Scientific,  Waltham,  
MA)  (Sriswasdi,  Harper  et  al.  2014).  Briefly,  cross-­linked  and  control  samples  were  
analyzed  in  parallel  using  LC-­MS/MS  and  a  label-­free  comparison  was  used  to  identify  
ions  specific  to  the  cross-­linked  samples.  Data  analysis  and  cross-­linked  peptide  
identification  was  performed  using  the  ZXMiner  program  (Sriswasdi,  Harper  et  al.  2014).  
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Cross-­links  for  DSG  and  DSS  were  analyzed  in  a  similar  fashion  using  xQuest/xProphet  
(Rinner,  Seebacher  et  al.  2008).  
High-­confidence  cross-­links  were  assigned  as  intra-­subunit,  inter-­subunit  or  
ambiguous  using  several  criteria.  Cross-­links  confidently  identified  in  the  monomer  band  
were  considered  to  be  intra-­subunit.  Cross-­links  observed  in  the  dimer  band  were  
considered  to  be  either  intra-­subunit  or  inter-­subunit  and  both  distances  were  calculated.  
A  difference  between  these  two  distances  of  more  than  11  Å  resulted  in  assignment  to  
the  shorter  distance  possibility.  Finally,  for  all  ambiguous  assignments,  the  crystal  
structure  was  visually  examined  using  PyMOL  for  the  presence  of  any  major  intervening  
structural  elements,  such  as  critical  dimer  interface  contacts  or  an  intervening  helix.  
2.2.4.  Homology  modeling  of  PRDX6  
The  PRDX6  protein  sequence  and  the  1PRX  crystal  structure  were  submitted  to  
MODELLER  9v11  (Sali  and  Blundell  1993)  to  generate  and  refine  human  PRDX6  
solution  structures.  All  modeling  experiments  were  run  as  50-­model  trials  using  the  “very  
slow”  refinement  algorithm  and  discrete  optimized  protein  energy  (DOPE)  score  as  an  
output.  Homology  modeling  and  refinement  were  performed  simultaneously  by  including  
known  intra-­  and  inter-­subunit  cross-­links  as  distance  restraints  between  α-­carbons  
imposed  at  11.0  +/-­  0.1  Å.  Each  model  was  subject  to  1,000  iterations  and  10  
optimization  repeats.  The  completed  models  were  then  analyzed  according  to  their  
DOPE  score,  and  the  highest-­scoring  model  under  this  criterion  was  chosen  for  further  
analysis.  Molecular  graphics  were  illustrated  using  Open-­Source  PyMOL  Version  1.3  
(Schrödinger,  LLC),  which  also  was  used  to  calculate  distances  between  α-­carbons  of  
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cross-­linked  glutamate,  aspartate,  and  lysine.  No  cross-­links  were  observed  involving  
the  N-­terminal  amine  group.  
2.3.  Results  and  Discussion  
2.3.1.  Analysis  of  CX-­MS  cross-­links  on  PRDX6  crystal  structure  
After  I  had  perofmed  the  LC-­MS  analysis  for  the  EDC/NHS  cross-­links  via  the  criteria  
described  in  Section  2.2.3,  I  used  ZXMiner  (Sriswasdi,  Harper  et  al.  2014)  to  identify  
potential  zero-­length  cross-­links  in  the  dimeric  protein.  Once  identified,  I  assigned  high  
confidence  cross-­links  as  intra-­subunit,  inter-­subunit  or  ambiguous  using  several  criteria.  
I  considered  cross-­links  confidently  identified  in  the  monomer  band  to  be  intra-­subunit.  I  
also  considered  cross-­links  observed  in  the  dimer  band  to  be  either  intra-­subunit  or  inter-­
subunit,  and  both  distances  were  calculated.  A  difference  between  these  two  distances  
of  more  than  11Å  resulted  in  assignment  to  the  shorter  distance  possibility.  Finally,  for  all  
ambiguous  assignments,  the  crystal  structure  was  visually  examined  using  PyMOL  
(Schrödinger,  LLC)  for  the  presence  of  any  major  intervening  structural  elements,  such  
as  critical  dimer  interface  contacts  or  an  intervening  helix.  
I  was  able  to  assign  at  least  12  of  15  high  confidence  zero-­length  cross-­links  I  
detected  as  either  intra-­subunit  or  inter-­subunit,  with  the  others  remaining  ambiguous.  
Surprisingly,  8  of  these  12  observed  distances  were  substantially  larger  than  the  
expected  12Å  or  16Å  limits  (see  Table  2-­1).  This  indicated  that  the  solution  structure  of  
the  reduced  form  of  the  enzyme  deviated  substantially  from  the  crystal  structure  (see  
Fig.  2-­1).  Therefore,  a  new  solution  structure  of  the  PRDX6  protein  had  to  be  developed.  
Table  2-­1:  Human  PRDX6  cross-­links  identified  using  EDC.  Reproduced  with  




Group   za   MH+  (Da)b  
Mass  
Error  





Inter-­Chain  Cross-­links                 
E01   4   1656.93474   4.6   AA[K]LAPEFAK   [E]LPSGK   19.8   56-­210  
E02   3   2640.42255   4.1   [E]LAILLGM#LDPAEKDEK   ELPSG[K]K   27.5   109-­215  
E03   3   2726.30843   5.7   DINAYNC(EE)PTEK   GVFT[K]ELPSGK   15.8   92/93-­209  
E04   5   3040.64670   5.3   LIALSIDSV[E]DHLAWSK   GVFT[K]ELPSGK   22.4   77-­209  
E05  
4,  
5   3044.62645   2.9   [E]LAILLGM#LDPAEKDEK   GVFT[K]ELPSGK   33.0   109-­209  
E06   4   3238.80547   4.2   ELAILLGM#LDPAEK[D]EK   VVISLQLTAE[K]R   28.4   123-­173  
E07  
3,  
4   3727.85644   1.8   ELAILLGM#LDPAE[K]DEK   (D)G(D)SVM#VLPTIPEEEAK   37.9   122-­183/185  
Intra-­Chain  Cross-­links                 
E08   3   1243.74389   6.2   [K]LFPK   [E]LPSGK   21.0   200-­210  
E09   3   1748.92572   5.0   GVFT[K]ELPSGK   YTPQ[P]   18.9   209-­224  
E10   4   1750.99291   4.9   [K]LFPKGVFTK   YTPQ[P]   12.6   200-­224  
E11   3   1943.10067   4.8   VVISLQLTAE[K]R   YTPQ[P]   7.0   173-­224  
E12  
3,  
4   2609.26208   4.5   AA[K]LAPEFAK   DINAYNC(EE)PTEK   10.3   56-­92/93  
Ambiguous  Cross-­linkse                 
E13   3   2514.39782   5.5   [E]LAILLGM#LDPAEKDEK   [K]LFPK   49.9  |  40.0   109-­200  
E14   5   2770.40894   1.3   FHDFLG[D]SWGILFSHPR   ELPSG[K]K   39.3  |  38.9   31-­215  
E15   4   2872.47512   5.2   AA[K]LAPEFAK   (D)G(D)SVMVLPTIPEEEAK   20.3  |  26.3   56-­183/185  
a  Observed  charge  states  of  the  cross-­linked  peptide.  
b  Observed  monoisotopic  mass  of  observed  peptide.  
c  []:  cross-­linked  residue;;  ():  potential  cross-­linked  residue  (ambiguous  location);;  #:  methionine  oxidation.  
d  All  distances  are  between  alpha-­carbons  of  cross-­linked  residues  in  the  human  PRDX6  crystal  structure  (PDB  ID:  
1PRX).  
e  Ambiguous  cross-­links  are  cross-­links  that  could  not  be  definitively  assigned  as  inter-­  or  intra-­molecular;;  both  
distances  are  described  in  the  table  entry,  separated  by  a  slash.  The  inter-­chain  distance  is  before  the  slash,  and  
the  intra-­chain  distance  is  after  the  slash.  
2.3.2.  Model  Development  and  Validation  
   I  used  MODELLER  as  described  in  Section  2.2.4  to  refine  the  1PRX  crystal  
structure  by  imposing  α-­carbon  distance  constraints  for  the  12  unambiguously  assigned  
cross-­links.  I  then  compared  the  resulting  preliminary  model,  hereafter  referred  to  as  the  
EDC1  model,  to  the  1PRX  crystal  structure  via  a  superposition  (see  Fig.  2-­4a).  I  saw  that  
most  major  structural  features  in  the  PRDX6  homodimer  remained  unchanged,  with  an  
overall  RMSD  of  1.4  Å.  Moreover,  an  analysis  of  the  Ramachandran  angles  using  Coot  
(Emsley,  Lohkamp  et  al.  2010)  for  this  model  also  revealed  that  over  90%  of  those  were  
found  in  preferred  or  allowed  conformations  for  EDC1,  reinforcing  the  validity  of  the  
model.  The  top  5  models  generated,  as  ranked  by  discrete  orbital  proximal  energy  




Fig.  2-­4.  Initial  Molecular  Model  of  human  PRDX6  using  EDC  Cross-­links.  
Reproduced  with  permission  from  (Rivera-­Santiago,  Harper  et  al.  2015).  (A)  
Superposition  of  the  crystal  structure  (blue)  and  EDC1  model  (red)  (RMSD:  1.4Å).  For  
simplicity,  only  the  A  chain  on  both  dimers  is  highlighted;;  both  B  chains  are  in  gray.  Cys-­
47  is  shown  in  yellow  sticks,  Cys-­91  is  shown  in  orange  sticks,  and  Thr-­177  is  shown  in  
light  green  sticks.  (B)  Close-­up  of  the  C-­terminal  region  on  chain  A,  which  shows  the  
largest  difference  relative  to  the  crystal  structure  (residues  190-­224).  (C)  α-­carbon  
distances  between  residues  identified  using  EDC  cross-­links  for  the  crystal  structure  and  
EDC1  model.  Expected  distance  cutoffs  are  12Å  for  well-­ordered  regions  (lower  black  
dashed  line),  and  16Å  for  disordered  regions  (upper  black  dashed  line).  (D)  α-­carbon  
distances  between  residues  with  ambiguous  assignments  as  to  whether  they  are  inter-­




The  EDC1  model  also  pinpointed  the  area  of  maximum  variability  between  the  
two  structures  as  involving  residues  190-­224  (see  Fig.  2-­4b),  with  an  RMSD  of  2.1  Å.  
The  distances  for  the  cross-­links  used  as  distance  restraints  were  all  below  the  16Å  
cutoff  point  (see  Fig.  2-­4c).  Additionally,  the  α-­carbon  distances  for  the  three  ambiguous  
cross-­links  that  I  did  not  use  in  this  structural  refinement  displayed  smaller  inter-­chain  
distances  compared  with  the  intra-­chain  distances  in  the  EDC1  model  (see  Fig.  2-­4d).  
This  trend,  coupled  with  the  observation  that  all  three  cross-­links  had  impeding  
intervening  structures  between  their  side  chains  for  a  putative  intra-­chain  cross-­link,  
enabled  me  to  assign  them  as  inter-­chain  cross-­links.  However,  their  distance  remained  
46  
  
larger  than  the  expected  16Å  cutoff,  which  indicated  that  I  needed  to  refine  my  model  
further.  
I  then  produced  a  second  model,  hereafter  referred  to  as  the  EDC2  model,  using  
MODELLER  to  refine  the  1PRX  crystal  structure  by  imposing  expected  α-­carbon  
distance  constraints  for  all  15  EDC  cross-­links.  Similar  to  the  EDC1  model,  most  major  
structural  features  in  the  PRDX6  homodimer  remained  unchanged  relative  to  the  crystal  
structure  with  an  overall  RMSD  of  1.7  Å  (see  Fig.  2-­5a)  and  the  area  of  maximum  
variability  between  the  two  structures  was  residues  190-­224  with  an  RMSD  of  2.9  Å  (see  
Fig.  2-­5b).  I  also  analyzed  this  model  via  Ramachandran  plot,  and  I  found  it  had  over  
90%  of  its  bond  angles  in  allowed  or  preferred  conformations.  As  before,  the  top  5  
models  by  DOPE  score  were  also  structurally  convergent.  In  this  model,  all  15  EDC  
cross-­links  were  now  within  the  16Å  maximum  distance  (see  Fig.  2-­5c-­d)  indicating  that  
all  zero-­length  cross-­link  data  supported  this  structure.    
Fig.  2-­5.  Molecular  Model  of  human  PRDX6  using  all  EDC  Cross-­links.  Reproduced  
with  permission  from  (Rivera-­Santiago,  Harper  et  al.  2015).  (A)  Superposition  of  the  
crystal  structure  (blue)  and  EDC2  model  (purple)  (RMSD:  1.7Å).  For  details  on  color  
schemes  and  highlighted  residues,  see  Fig.  4.  (B)  Close-­up  of  the  C-­terminal  region  on  
chain  A,  which  shows  the  largest  difference  relative  to  the  crystal  structure  (residues  
190-­224).  (C)  α-­carbon  distances  between  residues  identified  using  EDC  cross-­links  for  
the  crystal  structure  and  EDC2  model.  Expected  distance  cutoffs  are  12Å  for  well-­
ordered  regions  (lower  black  dashed  line),  and  16Å  for  disordered  regions  (upper  black  
dashed  line).  (D)  α-­carbon  distances  between  residues  with  initially  ambiguous  




Next,  I  performed  independent  CX-­MS  experiments  on  human  PRDX6  samples  
that  were  previously  cross-­linked  as  described  in  Section  2.2.2  using  the  homo-­
bifunctional  cross-­linkers  DSG  (H6/D6  mixture;;  7.7  Å  linker)  and  DSS  (H12/D12  mixture;;  
11.4  Å  linker)  to  further  evaluate  the  PRDX6  solution  structure  (see  Fig.  2-­3).  Unlike  the  
data  analysis  for  the  EDC  experiments,  these  cross-­linked  peptides  were  identified  using  
xQuest/xProphet  (Rinner,  Seebacher  et  al.  2008).  The  resulting  high  confidence  cross-­
links  (see  Tables  2-­2  and  2-­3)  were  mapped  onto  both  the  crystal  structure  and  the  
EDC2  structure  (see  Fig.  2-­6a-­b).  Because  the  lengths  of  the  spacer  arms  between  the  
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reactive  groups  of  these  cross-­linkers  (Paramelle,  Miralles  et  al.  2013),  I  used  maximum  
α-­carbon  distances  of  22Å  for  DSG  and  26Å  for  DSS,  which  is  consistent  with  previous  
studies  using  these  cross-­linkers  (Sriswasdi,  Harper  et  al.  2014).  
Table  2-­2:  Human  PRDX6  cross-­links  identified  using  DSG.  Reproduced  with  
permission  from  (Rivera-­Santiago,  Harper  et  al.  2015).  
Cross-­link  









Inter-­Chain  Cross-­links              
D01   4   1898.042   -­4.8   AA[K]LAPEFAK   ELPSG[K]K   56-­215  
D02d   4   1955.988   -­5.2   DE[K]GMPVTAR   ELPSG[K]K   125-­215  
D03   4   2302.258   0.5   GVFT[K]ELPSGK   AA[K]LAPEFAK   209-­56  
D04   4   2376.195   -­1.9   GVFT[K]ELPSGK   DE[K]GM#PVTAR   209-­125  
D05   4   2570.369   -­1.5   VVISLQLTAE[K]R   DE[K]GM#PVTAR   173-­125  
Intra-­Chain  Cross-­links              
D06   4   2630.409   -­0.1   L[K]LSILYPATTGR   DE[K]GMPVTAR   144-­125  
D07   4   2826.431   3.8   DGDSVM#VLPTIPEEEA[K]K   ELPSG[K]K   199-­215  
D08   3   2883.675   -­1.5   L[K]LSILYPATTGR   VVISLQLTAE[K]R   144-­173  
D09   5   3263.753   -­0.6   NV[K]LIALSIDSVEDHLAWSK   LAPEFA[K]R   67-­63  
Ambiguous  Cross-­links              
D10   4   2176.226   -­1.4   AA[K]LAPEFAK   LFP[K]GVFTK   56-­204  
a  Observed  charge  states  of  the  cross-­linked  peptide.  
b  Observed  monoisotopic  mass  of  observed  peptide.  
c  []:  cross-­linked  residue;;  ():  potential  cross-­linked  residue  (ambiguous  location);;  #:  methionine  oxidation.  
d  Multiple  variants  of  this  cross-­link  have  been  identified  in  this  dataset.  
Table  2-­3:  Human  PRDX6  cross-­links  identified  using  DSS.  Reproduced  with  
permission  from  (Rivera-­Santiago,  Harper  et  al.  2015).  
Cross-­
link  









Inter-­Chain  Cross-­links           
S01d   4   1940.09   -­4.2   AA[K]LAPEFAK   ELPSG[K]K   56-­215  
S02d   4   1998.038   -­3.7   DE[K]GMPVTAR   ELPSG[K]K   125-­215  
S03d   4   2344.296   -­3.6   GVFT[K]ELPSGK   AA[K]LAPEFAK   209-­56  
S04d   4   3469.896   -­0.8   ELAILLGM#LDPAE[K]DEK   L[K]LSILYPATTGR   122-­144  
S05   5   3523.839   -­3.7   ELAILLGM#LDPAE[K]DEKGM#PVTAR   ELPSG[K]K   122-­215  
Intra-­Chain  Cross-­links           
S06d   4   2688.448   -­1.6   L[K]LSILYPATTGR   DE[K]GM#PVTAR   144-­125  
S07   4   2925.727   0   L[K]LSILYPATTGR   VVISLQLTAE[K]R   144-­173  
S08   4   3830.905   -­0.8   DINAYNCEEPTE[K]LPFPIIDDR   AA[K]LAPEFAK   97-­56  
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a  Observed  charge  states  of  the  cross-­linked  peptide.  
b  Observed  monoisotopic  mass  of  observed  peptide.  
c  []:  cross-­linked  residue;;  ():  potential  cross-­linked  residue  (ambiguous  location);;  #:  methionine  oxidation.  
d  Multiple  variants  of  this  cross-­link  have  been  identified  in  this  dataset.  
Fig.  2-­6.  Evaluation  of  Solution  Structure  Using  Non-­Zero-­Length  Cross-­linkers.  
Reproduced  with  permission  from  (Rivera-­Santiago,  Harper  et  al.  2015).  (A)  Histogram  
analysis  of  α-­carbon  distances  between  residues  identified  using  DSG  cross-­links  for  the  
crystal  structure  (blue),  EDC2  model  (purple),  and  Final  model  (forest  green).  Expected  
distance  cutoff  is  22Å  (dashed  black  line).  (B)  Histogram  analysis  of  α-­carbon  distances  
between  residues  identified  using  DSS  cross-­links  for  the  crystal  structure,  EDC2  model,  
and  Final  model.  Expected  distance  cutoff  is  26Å.  (C)  Superimposition  of  the  crystal  
structure  (blue)  and  Final  model  (forest  green)  (RMSD:  1.6Å).  For  details  on  color  
schemes  and  highlighted  residues,  see  Fig.  4.  (D)  Superimposition  of  the  EDC2  model  




When  I  analyzed  the  1PRX  crystal  structure  using  these  cross-­links,  4  of  10  DSG  
cross-­links  exceeded  the  maximum  expected  distance  threshold.  This  confirms  that  the  
solution  structure  of  the  reduced  protein  significantly  differed  from  that  of  the  catalytic  
intermediate.  Interestingly,  3  of  these  4  cross-­links  were  within  expected  limits  when  the  
EDC2  model  was  considered.  For  DSS,  which  has  an  even  longer  spacer  arm,  none  of  
the  cross-­links  exceeded  the  threshold  for  that  cross-­linker  on  any  of  the  structures,  
which  indicated  the  inability  of  this  longer  spacer  arm  to  distinguish  between  PRDX6’s  
alternative  conformations.  I  then  evaluated  the  single  DSG  cross-­link  (hereafter  referred  
to  as  D10)  that  continued  to  exceed  the  expected  distance  threshold  in  the  EDC2  
structure.  Interestingly,  I  found  that  this  cross-­link  involved  Lys204,  which  is  located  
within  the  most  variable  region  of  the  protein  as  described  above.  D10  (see  Table  2-­2)  
51  
  
was  also  notable  because  its  assignment  as  an  inter-­chain  or  intra-­chain  cross-­link  was  
ambiguous  when  compared  to  the  1PRX  crystal  structure.  This  was  due  to  α-­carbon  
distances  of  30.3Å  and  36.3Å  for  inter-­chain  and  intra-­chain  interactions,  respectively.    
There  also  were  intervening  structural  elements  for  both  possible  types  of  cross-­link.  
However,  I  resolved  this  controversy  when  I  examined  it  on  the  EDC2  model,  as  the  
inter-­chain  interaction  no  longer  had  major  intervening  structural  elements  and  displayed  
an  α-­carbon  distance  of  26.1Å,  as  opposed  to  42.5Å  for  the  intra-­chain  interaction.  
In  order  to  further  explore  the  impact  of  the  D10  DSG  cross-­link  on  the  protein  
structure,  I  generated  a  final  solution  structure  using  MODELLER  to  refine  the  1PRX  
crystal  structure  further  by  imposing  expected  α-­carbon  distance  constraints  for  all  15  
EDC  cross-­links,  plus  the  D10  distance  constraint.  I  found  that  DSG  and  DSS  cross-­links  
were  within  expected  limits  in  this  model  (see  Fig.  2-­6a-­b).  Next,  I  compared  the  final  
structure  to  the  crystal  structure  (see  Fig.  2-­6c).  I  once  again  observed  that  the  overall  
backbone  structure  was  similar,  with  an  RMSD  of  1.6  Å  and  the  RMSD  of  the  C-­terminal  
tail  (residues  190-­224)  of  2.4  Å,  which  indicated  that  this  region  was  actually  slightly  
closer  to  the  crystal  structure  than  in  the  EDC2  model.  I  also  analyzed  this  model  was  
via  Ramachandran  plot,  and  once  again  I  found  that  over  90%  of  its  bond  angles  were  in  
preferred  or  allowed  regions.  The  top  5  models  by  DOPE  score  also  converged  
structurally.  The  final  model  was  also  directly  compared  to  the  EDC2  model  (see  Fig.  2-­
6d).  As  expected,  the  differences  between  the  EDC2  model  and  the  final  solution  
structure  were  minor,  with  an  overall  RMSD  of  0.74Å  and  an  RMSD  of  1.0  for  the  C-­





   In  summary,  I  was  able  to  use  structural  refinement  with  CX-­MS  distance  
constraints  to  determine  an  experimentally  validated  solution  structure  of  the  reduced  
form  of  PRDX6.  The  final  structure  fits  distance  constraints  of  all  high  confidence  cross-­
links  using  reagents  with  three  different  cross-­link  spacer  arms  (0,  7.7  and  11.4  Å).  
Consistent  with  what  was  observed  in  prior  CX-­MS  studies  by  the  Speicher  lab  and  
others  (Leitner,  Walzthoeni  et  al.  2010;;  Harper,  Sriswasdi  et  al.  2013;;  Sriswasdi,  Harper  
et  al.  2014;;  Sriswasdi,  Harper  et  al.  2014),  the  zero-­length  cross-­links  proved  to  be  the  
most  useful  for  identifying  conformational  differences  between  the  solution  structure  of  
the  reduced  protein  and  the  crystal  structure  of  the  catalytic  intermediate.  
In  contrast,  the  longest  cross-­linker  (DSS)  was  too  imprecise  for  me  to  
unambiguously  identify  any  discrepancies  between  the  solution  structure  and  the  crystal  
structure.  The  differences  between  the  solution  structure  and  crystal  structure  were  
mostly,  but  not  entirely,  located  within  the  C-­terminal  tail  of  the  protein  (residues  190-­
224).  This  region  is  primarily  comprised  of  coil,  which  probably  contributes  to  its  
plasticity.  However,  the  fact  that  all  33  distance  constraints  can  be  satisfied  by  a  single  
structure  suggests,  but  does  not  prove,  that  the  solution  structure  of  the  protein  as  
isolated  herein  is  primarily  a  single  conformation  rather  than  an  ensemble  of  inter-­
converting  structures.  
An  important  note  is  that  significant  changes  in  the  PRDX6  protein’s  structure  are  
not  limited  to  residues  190-­224.  Another  functionally  important  change  is  the  solvent  
accessibility  of  Thr-­177.  As  noted  above,  this  residue  is  phosphorylated  in  response  to  
certain  stimuli  and  increases  PLA2  activity  and  affinity  for  liposomes  (Wu,  Feinstein  et  al.  
2009),  but  it  is  completely  buried  in  the  crystal  structure.  In  contrast,  this  residue  is  
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substantially  solvent  exposed  in  my  EDC2  model  and  in  the  final  solution  structure  (see  
Fig.  2-­7).  Taken  together,  these  data  suggests  to  me  that  the  reduced  form,  should  be  
capable  of  being  phosphorylated,  but  not  the  oxidized  form  of  the  enzyme.  
Fig.  2-­7.  Surface  Accessibility  of  Thr-­177  in  PRDX6  Crystal  and  Solution  
Structures.  Reproduced  with  permission  from  (Rivera-­Santiago,  Harper  et  al.  2015).  
Closeup  of  protein  surface  display  for  Thr-­177  (green  spheres)  in  (A)  1PRX  crystal  
structure,  and  (B)  EDC2  solution  structure.  
  
I  also  evaluated  whether  the  conformational  differences  between  the  solution  and  
crystal  structures  correlated  with  the  most  flexible  regions  in  the  crystal  structure.  An  
analysis  of  the  Debye-­Waller  temperature  factors  (B-­factors)  in  the  crystal  structure  (see  
Fig.  2-­8a),  shows  that  residues  92-­93  and  121-­126  exhibited  the  highest  B-­factors.  The  
remainder  of  the  protein  had  B-­factors  less  than  40,  which  are  indicative  of  relatively  
rigid  structures.  A  comparison  of  residues  92-­93  in  the  crystal  structure  and  the  final  
solution  structure  show  that  this  coil  region  is  not  any  more  variable  than  its  flanking  
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regions  (see  Fig.  2-­8b).  Residues  121-­126  encompass  another  coil  region  that  also  does  
not  exhibit  substantially  greater  variability  between  structures  than  other  adjacent  coil  
regions.  
Fig.  2-­8.  Relationship  of  B-­factors  and  Variations  Between  the  PRDX6  Crystal  and  
Solution  Structures.  Reproduced  with  permission  from  (Rivera-­Santiago,  Harper  et  al.  
2015).  (A)  Analysis  of  B-­factors  for  1PRX  crystal  structure.  (B)  Superposition  of  1PRX  
crystal  structure  (blue)  and  Final  model  (forest  green)  highlighting  residues  Glu-­92  and  
Glu-­93  (orange  and  yellow  for  1PRX  and  Final,  respectively).  (C)  Superposition  of  1PRX  
crystal  structure  (blue)  and  Final  model  (forest  green)  highlighting  residues  Glu-­92  and  
Glu-­93  (orange  and  yellow  for  1PRX  and  Final,  respectively).  (D)  Superposition  of  1PRX  
crystal  structure  (blue)  and  Final  model  (forest  green)  highlighting  residues  190-­224  




Interestingly,  however,  this  region  is  significantly  more  compact  in  the  final  
solution  model  compared  with  the  crystal  structure  (see  Fig.  2-­8c).    Finally,  as  I  noted  
above,  the  C-­terminal  region  encompassed  by  residues  190-­224  shows  the  largest  
variation  between  the  two  structures  (see  Fig.  2-­8d),  but  this  region  does  not  have  high  
B-­factors  in  my  previous  analysis.  Interestingly,  an  analogous  region  in  2-­Cys  
peroxiredoxins  also  exhibits  conformational  change  as  part  of  the  catalysis  process  
(Wood,  Schroder  et  al.  2003).  
However,  one  key  difference  is  that  the  2-­Cys  C-­terminal  region  experiences  
localized  unfolding  in  response  to  the  breaking  of  a  disulfide  bond,  whereas  the  
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analogous  region  in  PRDX6  becomes  more  compact.  Overall,  I  did  not  see  a  strong  
correlation  between  regions  of  high  flexibility  in  the  crystal  structure  and  regions  involved  
in  conformational  changes  associated  with  transition  from  the  reduced  form  to  the  
peroxidase  catalytic  intermediate  form  of  the  enzyme.  That  suggests  that  these  
conformational  changes  play  an  important  role  in  the  catalytic  mechanism  and  do  not  
simply  reflect  variations  in  intrinsically  mobile  regions  of  the  protein.  It  also  suggests  that  
these  conformational  changes  associated  with  the  peroxidase  mechanism  could  help  
regulate  PLA2  activity.  That  is  to  say,  when  the  enzyme  is  in  the  reduced  form,  but  not  
the  catalytic  intermediate  state,  Thr-­177  is  solvent  exposed  and  can  be  phosphorylated  
thereby  increasing  PLA2  activity  and  affinity  for  liposomes.    
This  study  was  also  a  strong  showcase  for  the  advantages  of  using  zero-­length  
CX-­MS  for  probing  subtle  but  biologically  important  conformational  changes.  I  further  
demonstrated  the  resolving  power  of  zero-­length  CX-­MS  here  by  identifying  a  greater  
number  of  high-­confidence  cross-­links  EDC  (15  unique  cross-­link  sites)  as  compared  to  
DSG  (10  cross-­link  sites)  or  DSS  (8  cross-­link  sites).  This  larger  number  of  zero-­length  
cross-­links  was  identified  despite  less  extensive  overall  apparent  cross-­linking  relative  to  
the  DSG  and  DSS  reactions,  as  indicated  by  the  less  extensive  formation  of  covalently  
linked  homodimers  on  SDS  gels  (see  Fig.  2-­3).    More  importantly,  EDC  cross-­linking  
represented  the  most  sensitive  test  for  conformational  changes.  When  observed  cross-­
links  were  compared  to  the  crystal  structure,  8  of  12  EDC  cross-­links  (67%)  involved  
residues  that  were  further  apart  than  the  maximum  likely  distance,  whereas  only  4  of  10  




In  summary,  I  found  the  solution  structure  of  the  reduced  form  of  PRDX6  to  be  of  
particular  interest,  because  multiple  biochemical  studies  had  identified  conformational  
changes  of  the  protein  that  are  associated  with  changes  in  enzyme  activity  and  the  only  
reported  high  resolution  crystal  structure  is  of  the  peroxidase  catalytic  intermediate  form  
of  the  protein  (Choi,  Kang  et  al.  1998).  My  experimentally  supported  solution  structure  is  
consistent  with  multiple  biochemical  studies  that  indicate  PRDX6  is  a  protein  with  
substantial  plasticity  that  can  affect  both  known  enzyme  activities  of  this  protein.  It  also  
yields  novel  insights  regarding  the  nature  of  the  changes  that  occur  during  the  
peroxidase  catalysis  and  the  likely  interplay  between  regulation  of  the  two  enzyme  
activities  as  indicated  by  the  solvent  accessibility  of  Thr-­177.  The  reported  structure  
provided  me  with  an  important  structural  reference  for  this  protein,  as  the  reduced  form  
of  PRDX6  is  much  more  commonly  encountered  than  the  peroxidase  catalytic  










Chapter  3:  Optimizing  analysis  of  zero-­length  cross-­linked  peptides  using  Q  
Exactive  Plus  mass  spectrometer  
In  this  chapter,  I  will  discuss  efforts  made  to  optimize  the  zero-­length  CX-­MS  method  to  
a  more  state-­of-­the-­art  instrument.  Part  of  the  content  in  this  chapter  has  been  published  
as  a  manuscript  in  Methods  (Rivera-­Santiago,  Sriswasdi  et  al.  2015).  In  this  study,  Ms.  
Sandra  Harper  expressed,  purified,  and  cross-­linked  the  mini-­spectrin  protein  samples  
there  were  used  as  part  of  an  instrument  comparison.  I  then  performed  LC-­MS  and  
ZXMiner  analysis  on  the  cross-­links  in  order  to  generate  the  instrument  comparison  
table.  
3.1.  Background  
One  of  my  major  goals  for  the  zero-­length  CX-­MS  method  was  to  eventually  be  
able  to  interrogate  complex  protein  systems.  The  Speicher  laboratory,  including  myself,  
has  had  previous  success  with  purified  protein  samples  (Harper,  Sriswasdi  et  al.  2013;;  
Sriswasdi,  Harper  et  al.  2014;;  Rivera-­Santiago,  Harper  et  al.  2015),  and  the  method  to  
analyze  those  is  well-­established.  However,  I  would  like  to  expand  this  capability  to  
examine  more  complex  biologically  relevant  samples.  Furthermore,  I  wanted  to  do  so  in  
as  close  to  a  native  setting  as  possible,  in  order  to  maximize  the  relevance  of  the  
structural  information  I  am  gathering.  In  order  to  do  so,  I  needed  to  combine  an  optimal  
method  with  the  optimal  instrument  for  the  job.  
The  Speicher  lab  has  recently  come  into  the  possession  of  a  Thermo  Q  Exactive  
Plus  mass  spectrometer  (hereafter  referred  to  as  QE+),  which  is  a  significantly  different  
instrument  from  the  one  that  was  used  to  develop  the  zero-­length  CX-­MS  protocol  used  
in  previous  studies  (Harper,  Sriswasdi  et  al.  2013;;  Sriswasdi,  Harper  et  al.  2014;;  
Sriswasdi,  Harper  et  al.  2014;;  Rivera-­Santiago,  Harper  et  al.  2015),  which  was  the  
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Thermo  LTQ  Orbitrap  XL  mass  spectrometer,  as  described  in  Chapter  1.  One  of  the  
major  differences  lies  in  the  quality  of  MS  and  MS/MS  data  –  because  the  QE+  is  a  
much  more  state-­of-­the-­art  instrument  than  the  LTQ  Orbitrap  XL,  it  has  the  ability  to  
generate  significantly  more  MS/MS  spectra  per  full  scan,  thus  leading  to  significantly  
greater  depth  of  analysis.  This  increased  depth  of  analysis  results  in  the  elimination  of  
the  need  for  a  two-­part  discovery  and  targeted  approach,  as  the  QE+  is  entirely  capable  
of  collecting  high-­resolution  MS/MS  spectra  on  the  first  run.  The  impact  of  the  
differences  in  MS  data  collection  speed  and  quality  between  the  LTQ  Orbitrap  XL  and  
the  QE+  is  best  demonstrated  by  a  direct  comparison  analysis  between  the  two  
instruments.  We  performed  this  analysis  as  part  of  a  previous  study,  and  we  used  a  
purified  mini-­spectrin  (Harper,  Li  et  al.  2010)  protein  sample.  The  QE+  significantly  out-­
performs  the  LTQ  Orbitrap  XL  (see  Table  3-­1)  in  terms  of  both  instrument  time  required  
to  produce  the  data  as  well  as  number  of  total  and  unique  peptides  identified,  thus  
validating  our  interest  in  optimizing  the  instrument  parameters  for  it.  Moreover,  this  
difference  would  only  be  magnified  with  increasing  sample  complexity.  This  means  that  
optimizing  the  QE+  MS/MS  data  generation  and  analysis  pipeline  ties  into  the  long-­term  
goal  of  interrogating  more  complex  protein  samples.  
Table  3-­1:  Comparison  of  LTQ  Orbitrap  and  QE+  for  zero-­length  CX-­MS  
experiments  using  mini-­spectrina  





Totald   Uniqued  
Dimer   LTQ  Orbitrap   12   24   48   22  
Dimer   Q  Exactive  +   3   6   40   23  
Tetramer   LTQ  Orbitrap   12   24   71   38  
60  
  
Tetramer   Q  Exactive  +   3   6   107   59  
a  Reproduced  with  permission  from  (Rivera-­Santiago,  Sriswasdi  et  al.  2015).  
b  The  mini-­spectrin  band  used  for  the  in-­gel  digest.  
c  All  MS  runs  consisted  of  2-­hour  LC  gradients  and  injection  sizes  of  about  0.5  µg  of  protein.  
d  Peptides  have  FDR  =  0.0.  
In  spite  of  the  superior  high-­resolution  MS/MS  data  collection  capabilities  of  the  
QE+  instrument,  some  key  differences  between  the  QE+  and  the  LTQ  Orbitrap  XL  have  
to  be  taken  into  account.  One  such  difference  is  their  method  of  fragmenting  ions  for  
MS/MS  analysis.  The  LTQ  Orbitrap  XL  uses  its  ion  trap  to  fragment  ions  via  collision-­
induced  dissociation  (CID).  This  typically  ensures  that  no  ions  with  a  m/z  correspondent  
to  that  of  the  precursor  ion  remain.  Because  the  QE+  does  not  have  an  ion  trap  (it  is  a  
hybrid  quadrupole-­orbitrap  mass  spectrometer),  it  instead  performs  ion  fragmentation  via  
higher-­energy  collisional  dissociation  (HCD).  Because  of  this,  fragmentation  is  typically  
based  on  a  normalized  collision  energy  (NCE)  setting  specified  at  the  start  of  the  data  
acquisition  run.  What  this  typically  results  in  is  a  distribution  of  ions  that  were  properly  
fragmented,  ions  that  were  improperly  fragmented,  usually  resulting  in  MS3  ions,  and  
ions  that  were  not  fragmented  at  all,  thus  remaining  as  intact  precursor.  These  last  ions  
are  the  most  troublesome,  as  they  do  not  correspond  to  any  b-­  or  y-­ions  in  the  
fragmentation  pattern.  
In  order  to  address  this  issue,  I  decided  to  employ  a  two-­pronged  optimization  
strategy.  First,  I  optimized  the  parameters  for  the  zero-­length  CX-­MS  data  acquisition  
method  employed  by  the  QE+  instrument  in  order  to  maximize  the  depth  of  analysis.  
Secondly,  I  collaborated  with  Dr.  Sira  Sriswasdi,  Ms.  Sandra  Harper,  and  Dr.  David  W.  
Speicher  in  order  to  improve  the  ZXMiner  software  to  address  the  limitations  in  analysis  
of  QE+  data.  This  led  to  a  significant  improvement  in  the  quality  of  zero-­length  CX-­MS  
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data.  The  procedures  and  analysis  for  both  of  the  approaches  that  led  to  these  results  
are  described  below.  
3.2.  Methods  
3.2.1.  Preparation  of  erythrocyte  membrane  white  ghost  (WG)  samples  
Fresh  blood  samples  were  collected  from  healthy  volunteers  with  informed  
written  consent,  using  protocols  approved  by  the  The  Wistar  Institute  institutional  ethical  
review  board.    Erythrocyte  membranes,  commonly  called  “white  ghosts”  were  prepared  
by  Ms.  Sandra  Harper  as  described  in  Speicher,  et  al.  (Speicher,  Weglarz  et  al.  1992)  
with  several  modifications.    Briefly,  blood  was  stored  at  4  °C  for  2  days  prior  to  
processing  in  order  to  allow  reticulocyte  maturation.    After  centrifugation  (2000  x  g,  20  
min.,  4  °C)  and  removal  of  the  serum  and  buffy  coat,  the  packed  red  cells  were  diluted  to  
50%  hematocrit  in  10  mM  phosphate,  130  mM  sodium  chloride  pH  7.4  and  passed  
through  a  plasmodipur  filter  (Accurate  Chemical  and  Scientific  Corp,  Westbury,  NY)  to  
remove  any  contaminating  leukocytes.    The  filtered  sample  was  centrifuged  at  2000  x  g  
for  20  min  at  room  temperature.    The  supernatant  was  aspirated  and  the  red  cells  diluted  
to  50%  hematocrit  in  10  mM  phosphate,  130  mM  sodium  chloride  at  pH  7.4.    The  red  cell  
suspension  was  layered  onto  Lympholyte-­H  cell  separation  media  (Accurate  Chemical  
and  Scientific  Corp,  Westbury,  NY)  and  centrifuged  for  20  min  and  740  x  g  at  room  
temperature  to  remove  any  contaminating  lymphocytes.    The  supernatant  was  aspirated  
and  the  red  cells  were  diluted  in  10  mM  phosphate,  130  mM  sodium  chloride  at  pH  7.4.    
The  remaining  washing  and  lysis  steps  were  carried  out  as  previously  described.  This  
protocol  was  performed  twice  across  the  course  of  the  WG  parameter  optimization  trials.  
The  subsequent  samples  will  be  hereafter  referred  to  as  WG-­A  and  WG-­B.    
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3.2.2.  Cross-­linking  of  WG  samples  
   WG  samples  were  cross-­linked  using  a  previously  described  protocol  (Li,  Harper  
et  al.  2010;;  Sriswasdi,  Harper  et  al.  2014).  Briefly,  EDC  was  used  in  conjunction  with  
sulfo-­NHS  to  cross-­link  WG  samples  at  0  °C.  For  WG-­A,  aliquots  were  taken  at  30  
minutes  for  10  mM  EDC/5  mM  sulfo-­NHS.  For  WG-­B,  aliquots  were  taken  at  15,  30,  60,  
and  120  minutes  for  10  mM  EDC/5  mM  sulfo-­NHS,  and  at  15  and  30  minutes  for  20  mM  
EDC/10  mM  sulfo-­NHS.  The  reactions  were  then  quenched  by  adding  20  mM  DTT  and  
incubating  on  ice.  
3.2.3.  New  ZXMiner  software  
   I  collaborated  with  Ms.  Sandra  Harper,  Dr.  Sira  Sriswasdi,  and  Dr.  David  
Speicher  to  evaluate  GM  scores  for  ZXMiner  spectra  using  XlinkInspector  (see  Chapter  
1).  A  new  version  of  ZXMiner  (v.  0.2  beta)  was  developed  by  Dr.  Sriswasdi  and  used  for  
these  studies.  
3.2.4.  Parameter  optimization  for  QE+  instrument  
LC-­MS  runs  were  performed  on  the  WG  samples  described  above,  then  
analyzed  with  ZXMiner  v.  0.2  beta  using  the  same  parameters  as  in  previous  studies  
(Harper,  Sriswasdi  et  al.  2013;;  Sriswasdi,  Harper  et  al.  2014;;  Sriswasdi,  Harper  et  al.  
2014;;  Rivera-­Santiago,  Harper  et  al.  2015).  Parameters  were  compared  to  each  other  
based  on  their  performance  in  the  following  categories,  prioritized  as  presented:  
1.   Peptides  with  GM  scores  higher  than  the  highest-­scoring  false  positive  
(hereafter  referred  to  as  high-­confidence  IDs);;  
2.   Unique  peptides  with  GM  scores  higher  than  the  highest-­scoring  false  
positive  (hereafter  referred  to  as  unique  high-­confidence  IDs);;  
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3.   Peptides  with  GM  scores  lower  than  the  highest-­scoring  false  positive,  but  
higher  than  the  second-­highest  scoring  false  positive  (hereafter  referred  to  as  
high-­  and  medium-­confidence  IDs);;  
4.   Unique  peptides  with  GM  scores  lower  than  the  highest-­scoring  false  positive,  
but  higher  than  the  second-­highest  scoring  false  positive  (hereafter  referred  
to  as  high-­  and  medium-­confidence  IDs);;  
5.   Peptides  with  GM  scores  higher  than  0.2  (hereafter  referred  to  as  base  IDs);;  
6.   Unique  peptides  with  GM  scores  higher  than  0.2  (hereafter  referred  to  as  
unique  base  IDs);;  
7.   Total  entries.  
Parameter  optimization  experiments  for  LC  gradient  length,  m/z  peak  isolation  
width,  amount  protein  used  per  injection,  and  MS/MS  AGC  were  performed  on  WG-­A  
samples.  All  other  experiments  were  performed  on  WG-­B  samples.  All  experiments  run  
with  a  given  set  of  LC-­MS  parameters  for  WG-­B  were  considered  to  be  a  single  
experiment  in  data  analysis  via  ZXMiner.  
3.3  Results  and  Discussion  
In  order  to  optimize  the  parameters  on  the  QE+  for  zero-­length  CX-­MS,  I  
collaborated  with  Ms.  Sandra  Harper,  Dr.  Sira  Sriswasdi,  and  Dr.  David  Speicher  to  
determine  how  to  best  account  for  the  differences  in  LTQ  Orbitrap  XL  spectra  and  QE+  
spectra  that  contributed  to  the  lower  the  GM  scores  for  QE+  data.  A  summary  of  the  
process  by  which  these  GM  scores  are  generated  is  presented  in  Fig.  3-­1.  We  decided  
that  the  presence  of  peaks  in  the  precursor  ion  region  was  the  most  important  factor.  To  
address  this,  Dr.  Sriswasdi  developed  a  new  version  of  ZXMiner  (version  0.2  beta).  
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Fig.  3-­1:  Summary  of  geometric  mean  (GM)  score  determination  for  ZXMiner  data.  
a.  Peak  coverage  represents  score  for  proportion  of  peaks  assigned  as  b-­  or  y-­ions,  
precursor-­related  ions,  or  neutral  losses  (scored  from  0-­1);;  b.  Ion  coverage  represents  
proportion  of  total  b-­  and  y-­ions  assigned  for  an  MS/MS  spectrum  (scored  from  0-­1);;  c.  
Intensity  coverage  represents  proportion  of  total  peptide  intensity  assigned  as  b-­  or  y-­
ions,  precursor-­related  ions,  or  neutral  losses  (scored  from  0-­1).  d.  delta-­GM  score  
represents  the  user-­assigned  parameter  that  describes  the  minimum  difference  between  
GM  scores  for  the  highest-­scoring  match  and  the  second-­highest-­scoring  match  for  a  




I  then  also  consulted  with  Dr.  David  W.  Speicher  as  well  as  with  Dr.  Craig  
Dufresne,  an  Orbitrap  specialist  at  Thermo  Scientific  who  presented  a  training  session  
on  the  QE+  instrument  that  I  attended.  After  consulting  with  them,  I  came  up  with  a  list  of  
parameters  to  test  by  running  LC-­MS  runs  of  roughly  equivalent  white  ghost  (WG)  
samples  under  all  chosen  variations,  then  comparing  the  number  of  various  categories  
of  peptides  (see  Section  3.2.4).  This  resulted  in  a  total  of  25  discrete  experiments.  
After  completing  these  experiments,  the  analysis  of  the  various  parameters  for  
the  QE+  instrument  revealed  several  things.  The  first  was  that  most  of  these  parameters  
had  a  predictable  impact  on  QE+  data.  One  of  the  most  surprising  effects  was  that  the  
results  of  the  peptide  match  (PM)  setting.  PM  is  a  parameter  that  restricts  the  selection  
of  precursor  ions,  and  their  subsequent  MS/MS  fragmentations,  to  ideal  isotopic  
envelopes  when  in  the  “on”  setting  (hereafter  referred  to  as  PM(on)).  An  ideal  isotopic  
envelope  is  typically  one  that  has  a  smooth  abundance  distribution  centered  on  any  one  
peak,  and  whose  charge  state  can  be  identified  by  the  instrument.  PM  being  in  the  
“preferred”  setting  (hereafter  referred  to  as  PM(pref))  means  that  if  the  preset  number  of  
MS/MS  scans  for  the  N  most  intense  peptides  in  a  full  MS  run  (commonly  referred  to  as  
TopN)  has  not  been  met,  it  will  choose  a  peak  from  those  which  means  that  at  least  
some  of  our  zero-­length  CX-­MS  IDs  are  coming  from  those  non-­ideal  envelopes.  This  
could  be  due  to  the  fact  that  low  abundance  cross-­links  will  typically  produce  low  
abundance  ions,  and  thus  the  envelopes’  shape  could  be  affected  by  small  sample  
sizes.  
   Another  surprising  development  was  that  exclusion  lists  were  only  conditionally  
useful  for  runs  where  PM  (on)  peptide  runs,  and  essentially  identical  to  a  run  not  using  
the  exclusion  list  whe  PM  (pref)  was  used.  This  could  be  due  to  the  lack  of  interference  
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in  MS/MS  spectra  in  the  intervening  region.  Another  possibility  is  that  the  ions  being  
eliminated  by  the  exclusion  list  were  relatively  low  in  abundance.  Lastly,  the  length  of  
MS/MS  fill  time  had  a  very  small  impact,  which  again  suggests  that  zero-­length  CX-­MS  
precursor  ions  are  low  in  abundance.  
After  this  optimal  method  was  determined,  I  then  compared  the  first  full  MS/MS  
White  Ghost  dataset  creating  using  samples  from  WG-­B  (see  Section  2.2.1)  generated  
during  these  parameter  optimization  trials  to  the  one  determined  to  be  most  optimal  
according  to  the  parameters  described  in  Table  3-­2.  This  comparison  (see  Table  3-­3)  
clearly  illustrates  that  significant  improvements  have  been  made  in  the  zero-­length  CX-­
MS  method  using  these  techniques.  
Table  3-­2:  Parameters  used  in  QE+  method  optimization  trials.  Preferred  parameters  
shown  in  bold.  
Parameter   Iterations  Tested  
LC  gradient  length  (hours)   2  hoursa;;  4  hours  
m/z  peak  isolation  width  (au)   1.5  aua;;  3.0  au  
Amount  of  protein  used  per  injection(µg)   1  µga;;  3  µg  
Repeat  analyses   Duplicatesb  
MS/MS  AGC  (ions)   1  x  105  ions;;  1  x  106  ionsa  
MS/MS  duty  cycle   Top-­10;;  Top-­20b  
MS/MS  fill  time  (ms)   120  msb;;  240  ms  
Excluded  charge  states  (z)   +1,  +2a;;  +1,  +2,  +3  
Peptide  match  (PM)  setting   PM(on);;  PM(preferred)a  
Exclusion  lists   PM  (on)b;;  PM  (preferred)  
Target  lists  (LC-­MS  re-­analysis)   All  IDs;;  positive  IDsa  
a  This  parameter  had  a  major  impact  on  data  quality.  
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b  This  parameter  had  a  minor  impact  on  data  quality.  
  
Table  3-­3:  Method  peptide  yield  comparison  for  QE+  zero-­length  CX-­MS  
optimization  trials.  
Parameter   Pre-­Optimization  Method  
Post-­Optimization  
Method  
Total  Entries   174   320  
High-­Confidence  IDsa   33   65  
Unique  High  Confidence  IDsa   28   46  
High-­  and  Medium-­Confidence  IDsb   46   87  
Unique  High-­  and  Medium-­Confidence  
IDsb   38   63  
Base  IDsc   105   179  
Unique  Base  IDsc   84   146  
a  Peptide  IDs  with  a  GM  score  greater  than  the  highest-­scoring  false  positive  in  their  respective  
LC-­MS  experiment.  
b  Peptide  IDs  with  a  GM  score  greater  than  the  second-­highest-­scoring  false  positive  in  their  
respective  LC-­MS  experiment.    
c  Peptide  IDs  with  a  GM  score  greater  than  0.2.  
3.4  Summary  
   In  summary,  a  concerted  effort  was  made  to  adapt  the  zero-­length  CX-­MS  
method  to  a  more  state-­of-­the-­art  QE+  mass  spectrometer,  as  opposed  to  the  LTQ  
Orbitrap  XL  instrument  that  was  used  in  previous  studies  (Harper,  Sriswasdi  et  al.  2013;;  
Sriswasdi,  Harper  et  al.  2014;;  Sriswasdi,  Harper  et  al.  2014;;  Rivera-­Santiago,  Harper  et  
al.  2015).  In  order  to  do  so,  differences  in  MS/MS  ion  fragmentation  were  addressed  via  
a  new  version  of  ZXMiner.  Extensive  parameter  optimization  was  also  undertaken  in  
order  to  identify  the  best  parameters  to  use  for  the  QE+  instrument  (see  Table  3-­2).  This  
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resulted  in  dramatic  improvement  of  the  zero-­length  CX-­MS  method  (see  Table  3-­3),  
















Chapter  4:  Determination  of  structure  for  full-­length  anion  exchanger  1  (AE1)  via  
zero-­length  CX-­MS  
4.1.  Background  
As  mentioned  in  Chapter  3,  one  of  the  major  systems  I  was  interested  in  
examining  with  our  optimized  zero-­length  CX-­MS  technique  was  the  erythrocyte  
membrane.  Specifically,  my  interests  lay  in  determining  the  structures  of  the  major  
protein  components  of  the  erythrocyte  membrane.  These  components  are  critically  
involved  in  giving  these  membranes  their  trademark  elasticity  and  structural  integrity  
(Fairbanks,  Steck  et  al.  1971).  Secondly,  because  of  their  high  relative  abundance,  the  
major  structural  proteins  of  the  erythrocyte  membrane  will  be  likely  to  produce  multiple  
peptide  Identifications.  These  will  in  turn  provide  me  with  sufficient  information  to  create  
experimentally  validated  structural  models  of  key  membrane  components.  This  would  be  
novel  information,  as  most  previous  analyses  that  have  modeled  erythrocyte  membrane  
proteins  have  been  composed  of  speculative  models  based  on  very  limited  structural  
data,  combined  with  biochemical  data  from  previous  studies  (Burton  and  Bruce  2011;;  
Mankelow,  Satchwell  et  al.  2012).  
I  was  particularly  interested  in  the  anion  exchanger  1  (AE1)  protein,  in  large  part  
because  it  plays  a  critical  organizing  role  for  all  major  erythrocyte  membrane  skeleton  
complexes  (Fairbanks,  Steck  et  al.  1971;;  van  den  Akker,  Satchwell  et  al.  2010;;  Choi  
2012).  These  skeleton  complexes,  which  include  the  actin  junctional  complex  (Salomao,  
Zhang  et  al.  2008;;  Anong,  Franco  et  al.  2009)  and  the  ankyrin-­spectrin  complex  (Davis,  
Lux  et  al.  1989;;  Grey,  Kodippili  et  al.  2012)  (see  Fig.  4-­1),  are  unique  to  the  erythrocyte  
membrane  and  have  been  shown  to  provide  it  with  the  flexibility  and  elasticity  that  was  
previously  described  (van  den  Akker,  Satchwell  et  al.  2010).  Moreover,  mutations  and  
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other  anomalies  in  AE1  are  also  involved  in  a  variety  of  disease  states  (Tanner  2002;;  
Stehberger,  Shmukler  et  al.  2007).  These  include  aberrant  erythrocyte  shapes  (Yusoff,  
Van  Rostenberghe  et  al.  2003;;  Alper  2009),  hemolytic  anemia  (Eber  and  Lux  2004;;  
Gallagher  2005;;  An  and  Mohandas  2008;;  Perrotta,  Gallagher  et  al.  2008),  and  
deficiencies  or  changes  in  ion  transport  (Cheung,  Cordat  et  al.  2005;;  Cheung,  Li  et  al.  
2005;;  Cheung  and  Reithmeier  2005;;  Takazaki,  Abe  et  al.  2010;;  Barneaud-­Rocca,  
Borgese  et  al.  2011).  Finally,  because  AE1  is  the  single  most  abundant  protein  in  the  
erythrocyte  membrane  (Fairbanks,  Steck  et  al.  1971),  it  is  very  likely  to  provide  the  depth  
of  analysis  required  to  generate  a  structure  with  a  high  degree  of  confidence.  
Fig.  4-­1:  Diagram  of  the  protein  complexes  in  the  erythrocyte  membrane  in  
relation  to  AE1.  Reproduced  with  permission  from  (van  den  Akker,  Satchwell  et  al.  






AE1,  also  known  as  band  3,  is  a  911-­residue  protein  that  is  primarily  expressed  
in  erythrocytes  (Fairbanks,  Steck  et  al.  1971)  and  acid-­secretory  intercalated  kidney  cells  
(Brosius,  Alper  et  al.  1989)  and  is  composed  of  2  major  domains:  a  N-­terminal  region  
that  is  involved  in  recruiting  and  binding  of  multiple  membrane  skeleton  protein  
complexes  (residues  1-­360),  and  a  C-­terminal  region  involved  in  anion  transport  that  
includes  many  transmembrane  segments  (residues  361-­911)  (Lepke  and  Passow  1976;;  
Grinstein,  Ship  et  al.  1978;;  Kopito  and  Lodish  1985;;  Choi  2012).  Specifically,  it  neutrally  
exchanges  bicarbonate  (HCO3-­)  ions  generated  by  carbonic  anhydrase  for  chloride  (Cl-­)  
ions,  thereby  performing  a  critical  role  in  carbon  dioxide  (CO2)  processing  (Passow  
1986).  It  exists  as  a  mix  of  dimers  and  tetramers  in  the  erythrocyte  membrane,  with  its  
oligomeric  state  being  indicative  of  the  protein  complexes  it  is  anchoring  (van  den  Akker,  
Satchwell  et  al.  2010).  Disruption  of  AE1’s  ability  to  form  these  protein  complexes  has  
been  implicated  in  the  disease  states  mentioned  above  (Tanner  2002).    
The  N-­terminal  region  of  AE1,  also  referred  to  in  the  literature  as  the  cytoplasmic  
domain  of  band  3,  or  cdb3,  is  by  far  the  better-­characterized  region  of  the  protein.  Two  
crystal  structures  of  this  region  have  been  determined,  and  these  describe  most  of  the  
domain.  The  only  region  of  cdb3  that  is  poorly  characterized  is  the  extreme  N-­terminus,  
which  is  disordered  in  solution  (Zhang,  Kiyatkin  et  al.  2000;;  Shnitsar,  Li  et  al.  2013).  On  
the  other  hand,  the  structure  of  the  C-­terminal  region  was  much  less  clear  when  I  started  
this  project.  A  variety  of  biochemical  and  structural  studies  have  been  conducted  on  this  
region  (Wang,  Kuhlbrandt  et  al.  1993;;  Wang,  Sarabia  et  al.  1994;;  Tang,  Fujinaga  et  al.  
1998;;  Fujinaga,  Tang  et  al.  1999;;  Popov,  Li  et  al.  1999;;  Taylor,  Zhu  et  al.  2001;;  Zhu,  Lee  
et  al.  2003;;  Cheung  and  Reithmeier  2005;;  Barneaud-­Rocca,  Borgese  et  al.  2011),  
including  a  partial  structural  characterization  by  cryo-­electron  microscopy  (EM)  at  a  
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resolution  of  7.5  Å  (Yamaguchi,  Ikeda  et  al.  2010).  However,  the  composition  of  the  
membrane  domain  of  AE1,  including  its  number  of  transmembrane  spans,  was  still  in  
contention.  Although  several  studies  have  theorized  that  the  ion  transporter  region  is  
composed  of  12  transmembrane  spans,  this  is  not  the  consensus  in  the  field.  Recently,  a  
study  evaluated  the  AE1  biochemical  evidence  along  with  the  cryo-­EM  structure  and  
proposed  various  topology  models  (all  with  14  helical  transmembrane  spans)  in  an  effort  
to  consolidate  the  discussion  on  the  issue  (Hirai,  Hamasaki  et  al.  2011).  These  
unresolved  controversies  combined  with  the  importance  of  the  AE1  protein  to  make  it  a  
very  attractive  research  target.  
4.2.  Methods  
A  flowchart  of  the  experimental  strategy  using  chemical  cross-­linking  and  
molecular  modeling  to  develop  a  structure  of  the  full-­length  AE1  protein  is  summarized  in  
Fig.  4-­2.  
Fig.  4-­2:  Flowchart  showing  the  strategy  use  to  generate  my  full-­length  AE1  
structure.  Colors  indicate  the  corresponding  programs  used  in  the  progression  of  these  
experiments,  with  ZXMiner  v.  0.2  (beta)  (Sriswasdi,  Harper  et  al.  2014)  in  blue,  
MODELLER  9v14  (Sali  and  Blundell  1993)  in  purple,  and  Phyre2  (fold  library  April  4,  





4.2.1.  White  Ghost  CX-­MS  
For  this  study,  ZXMiner  v.  0.2  beta  (Sriswasdi,  Harper  et  al.  2014)  analyses  were  
performed  on  the  White  Ghost  (WG)  samples  initially  used  to  optimize  depth  of  analysis  
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on  the  QE+  mass  spectrometer  (see  Section  3.2.1  for  details).  Briefly,  those  experiments  
involved  a  variety  of  cross-­linked  WG  samples  run  under  different  instrument  parameters  
(see  Table  3-­2  for  details),  which  were  then  evaluated  for  their  magnitude  of  effect  on  
cross-­linked  identification.  The  parameters  used  for  ZXMiner  were  as  described  in  
previous  studies  (Harper,  Sriswasdi  et  al.  2013;;  Sriswasdi,  Harper  et  al.  2014;;  Sriswasdi,  
Harper  et  al.  2014;;  Rivera-­Santiago,  Harper  et  al.  2015).  Briefly,  a  precursor  mass  
tolerance  of  10ppm,  a  minimum  GM  score  of  0.2,  a  minimum  ion  coverage  score  of  0.1,  
and  a  minimum  ΔGM  score  (which  is  defined  as  the  minimum  difference  in  GM  an  
identification  must  have  from  all  other  possible  identifications  in  order  to  be  considered  a  
true  identification)  were  imposed.  
After  the  cross-­link  identifications  and  corresponding  GM  scores  were  generated,  
the  following  criteria  were  applied  in  order  to  assign  confidence  intervals  for  the  
identifications:  
1.   All  identifications  with  a  GM  score  under  0.2  were  not  considered.  This  
GM  score  cutoff  is  in  accordance  with  the  minimum  base  identification  score  
considered  in  our  optimization  experiments  for  the  QE+  instrument  (see  Section  
3.2.4).  
2.   All  identifications  with  a  GM  score  higher  than  that  of  the  highest-­scoring  
false  positive  score  for  the  file  in  which  they  were  generated  were  considered  
high-­confidence  identifications.  
3.   All  identifications  with  a  GM  score  between  the  highest-­scoring  false  
positive  identification  and  the  second-­highest-­scoring  false  positive  identification  
were  considered  medium-­confidence  identifications.  
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4.   All  high-­  and  medium-­confidence  identifications  were  analyzed  utilizing  
XlinkInspector  version  2.1,  and  manually  reassigned  as  high-­  or  medium-­
confidence  cross-­link  identifications  based  on  the  following  criteria:  
A.   A  high-­confidence  cross-­link  identification  will  have  identified  at  
least  50%  of  the  peaks  present  in  its  MS/MS  spectrum.  
B.   A  high-­confidence  cross-­link  identification  will  have  identified  the  3  
most  intense  peaks  present  in  its  MS/MS  spectrum.  
C.   A  high-­confidence  cross-­linked  peptide  identification  will  have  an  
unambiguously  clear  residue  assignment  of  the  cross-­linked  residues.  
This  was  defined  as  an  identification  that  has  one  cross-­linked  residue  
assignment  that  can  be  visualized  in  XlinkInspector  that  has  a  GM  score  
higher  than  all  of  the  alternative  possible  cross-­linked  residue  
assignments  for  those  cross-­linked  peptides.  
5.   Once  all  high-­  and  medium-­confidence  cross-­link  identifications  were  re-­
evaluated,  the  cross-­links  that  resulted  from  these  identifications  across  samples  
were  re-­examined.  Any  cross-­link  Identifications  that  only  corresponded  to  
medium-­confidence  identifications  were  not  considered  further.  
4.2.2.  Immunoprecipitation  and  zero-­length  CX-­MS  of  AE1  
Immunoprecipitation  (IP)  reactions  were  designed  in  collaboration  with  Mr.  Peter  
Hembach  and  Ms.  Sandra  Harper  of  the  Speicher  lab.  The  WG  protein  consisted  of  200  
µg  of  total  protein  at  a  concentration  of  2  µg/µL  in  50  mM  Tris,  150  mM  NaCl,  1  mM  
EDTA,  and  0.5%  SDS  at  pH  =  7.4.  This  protein  had  been  previously  prepared  and  cross-­
linked  using  10  mM  EDC  and  5  mM  sulfo-­NHS  for  0,  30,  60,  and  120-­minute  intervals  at  
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0  °C.  A  10-­µg  untreated  sample  (WG  Untr)  was  set  aside  before  the  IPs.  These  WG  
samples  were  passed  through  a  Dynabead  magnetic  bead  column  with  a  conjugated  
polyclonal  AE1  antibody  (Abcam  product  number  ab78067),  then  washed  with  TEA  at  
pH  =  11.5.  This  column  was  prepared  by  binding  800mg  of  antibody  to  1.8  mL  of  
Dynabeads  Prot.  G,  then  cross-­linking  and  running  a  blank  elution  with  TEA  at  pH  =  
11.5,  then  neutralizing  with  160  mL  of  2M  Tris  at  pH  =  6.0.  500  µL  of  Dynabead  slurry  (at  
a  1  µg/µL  concentration)  was  used  per  IP  experiment,  and  the  flow-­through,  wash,  and  
elution  fractions  were  collected  by  spinning  in  a  JA-­20.1  centrifuge  at  16,000  rpm  for  20  
min.,  then  removing  the  supernatant.  
Various  elution  solvents  (glycine  +  1%  NP-­40  at  pH  2.5,  TEA  +  1%  NP-­40  at  pH  
11,  imidazole  +  6M  urea  +  1%  NP-­40  at  pH  6.0,  glycine  +  NaCl  +  6M  urea  +  1%  NP-­40  
at  pH  2.5)  were  tested  in  parallel  experiments.  Each  elution  was  performed  in  triplicate,  
then  the  subsequent  elution  fractions  was  then  concentrated  using  a  100kDa  
ultrafiltration  device.  The  WG  Untr,  flow-­through,  wash,  and  elution  fractions  were  then  
analyzed  via  SDS-­PAGE  using  equivalent  protein  loads,  as  well  as  by  a  Western  blot  
using  a  monoclonal  anti-­AE1  antibody  (MAb-­X-­DyBPA)  (see  Fig  4-­3).  This  Western  blot  
was  exposed  for  30  seconds,  then  developed.  
Eluent  fractions  were  then  analyzed  via  SDS-­PAGE  gels  run  for  2cm  to  
determine  what  bands  would  be  selected  for  LC-­MS/MS  (see  Fig.  4-­4).  After  bands  were  
selected,  they  were  analyzed  using  the  most  optimal  LC-­MS  protocol  determined  as  part  
of  the  parameter  optimization  trials  (see  Table  3-­2).  ZXMiner  analyses  on  these  samples  
used  the  same  parameters  as  previously  described.  
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4.2.3.  Development  of  AE1  transmembrane  model  
Phyre2  (Kelley,  Mezulis  et  al.  2015)  (fold  library  April  4,  2015)  was  used  to  
develop  a  template  structure  for  the  AE1  transmembrane  domain,  using  residues  380-­
911  from  the  primary  sequence  of  AE1  as  input.  This  structure  was  evaluated  using  the  
available  published  biochemical  data,  as  well  as  the  previously  generated  AE1  topology  
model  (see  Section  4.3.3  for  details).  
4.2.4.  Combinatorial  modeling  
The  validated  AE1  C-­terminal  domain  template,  the  AE1  protein  sequence,  and  
the  1PRX  crystal  structure  were  submitted  to  MODELLER  9v14  to  generate  and  refine  
human  AE1  a  complete  structure  for  full-­length  AE1.  All  modeling  experiments  were  run  
as  50-­model  trials  using  the  “very  slow”  refinement  algorithm  and  discrete  optimized  
protein  energy  (DOPE)  score  as  an  output.  Homology  modeling  and  refinement  were  
performed  simultaneously  by  including  known  intra-­  and  inter-­subunit  cross-­links  as  
distance  restraints  between  α-­carbons  imposed  at  11.0  +/-­  0.1  Å.  Each  model  was  
subject  to  1,000  iterations  and  10  optimization  repeats.  The  completed  models  were  
then  analyzed  according  to  their  DOPE  score,  and  the  highest-­scoring  model  under  this  
criterion  was  chosen  for  further  analysis.  Molecular  graphics  were  illustrated  using  
Open-­Source  PyMOL  Version  1.7.x,  which  also  was  used  to  calculate  distances  
between  α-­carbons  of  cross-­linked  glutamate,  aspartate,  and  lysine.  No  cross-­links  were  
observed  involving  the  N-­terminal  amine  group.  
4.3.  Results  and  Discussion  
4.3.1.  White  ghost  CX-­MS  
In  order  to  elucidate  additional  information  about  the  correlation  between  
identified  AE1  cross-­links  and  the  protein’s  oligomeric,  as  well  as  attempt  to  increase  the  
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depth  of  analysis  for  AE1  cross-­links  in  particular,  I  collaborated  with  Mr.  Peter  Hembach  
and  Dr.  David  Speicher.  We  designed  a  series  of  immunoprecipitation  (IP)  experiment  
for  AE1  and  any  proteins  cross-­linked  to  it  via  a  magnetic  bead  column  with  a  
conjugated  polyclonal  AE1  antibody  (see  Section  4.2.2  for  details).  The  quality  of  elution  
would  then  be  detected  via  Western  blots  using  a  monoclonal  AE1  antibody  (see  Fig.  4-­
3).  We  settled  on  a  procedure  that  involved  washing  the  column  using  TEA,  and  then  
eluting  with  1%  NP-­40  and  glycine  at  pH  2.5.  The  elution  fraction  was  then  concentrated  
using  a  100kDa  ultrafiltration  device.  The  flow-­through,  wash,  and  elution  fractions  were  
collected,  then  analyzed  via  SDS-­PAGE  as  well  as  a  Western  blot  using  a  monoclonal  
anti-­AE1  antibody  (see  Section  4.2.2  for  details).  
Fig.  4-­3:  Immunoprecipitation  Western  blots  for  AE1.  Elution  conditions  are  
described  in  the  relevant  lanes.  Three  alternative  elution  conditions  were  testing  using  
replicate  immunoprecipitation  samples  and  two  sequential  elutions  were  evaluated  for  
each  condition  to  verify  the  completeness  of  the  elution.  S  =  supernatant  for  cross-­linked  
WG  samples.  P  =  pellet  for  cross-­linked  WG  samples.  U  =  unbound  fraction  from  WG  
immunoprecipitation  experiments.  W1  =  initial  wash.  W3  =  Final  wash  to  test  column  
reusability.  Red  boxed  area  indicates  elution  1  using  glycine  and  1%  NP-­40  at  pH=2.5  
[White  Ghost  samples  were  prepared  and  cross-­linked  by  Sandra  Harper.  IP  




4.3.2.  Immunoprecipitation  and  zero-­length  CX-­MS  of  AE1  
In  order  to  elucidate  additional  information  about  the  correlation  between  
identified  AE1  cross-­links  and  the  protein’s  oligomeric  state,  as  well  as  attempt  to  
increase  the  depth  of  analysis  for  AE1  cross-­links  in  particular,  I  collaborated  with  Ms.  
Sandra  Harper  and  Mr.  Peter  Hembach  in  our  laboratory.  We  designed  a  series  of  
immunoprecipitation  (IP)  experiments  for  AE1  and  any  proteins  cross-­linked  to  it  via  a  
magnetic  Dynabead  column  with  a  conjugated  polyclonal  AE1  antibody.  The  quality  of  
elution  would  then  be  detected  via  Western  blots  using  a  monoclonal  AE1  antibody  (see  
Fig.  4-­3).  We  settled  on  a  procedure  that  involved  washing  the  column  using  TEA,  and  
then  eluting  with  1%  NP-­40  and  glycine  at  pH  2.5.  The  elution  fraction  was  then  
concentrated,  then  analyzed  along  with  the  flow-­through  and  wash  fractions  via  SDS-­
PAGE  as  well  as  by  a  Western  blot  using  a  monoclonal  anti-­AE1  antibody  (see  Section  
4.2.2  for  details).  Next,  the  AE1  samples  were  run  on  an  SDS-­PAGE  gel  for  2cm,  and  
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the  bands  that  corresponded  to  AE1  monomers,  dimers,  and  tetramers  were  cut  out  and  
analyzed  by  LC-­MS  (see  Fig.  4-­4).  This  was  a  total  of  7  experiments.  
Fig.  4-­4:  AE1  Immunoprecipitations  used  to  identify  association  between  cross-­
linked  peptides  and  different  oligomeric  states.  SM  indicates  IP  of  an  uncross-­linked  
control  white  ghost  (WG)  sample.  Lanes  labeled  WG  Untr.  are  for  control  samples  that  
were  neither  cross-­linked  nor  immunoprecipitated.  Numbers  under  cross-­linked  samples  
indicate  the  length  of  the  initial  cross-­linking  reaction.  The  gel  of  the  left  was  separated  
by  SDS-­PAGE  until  the  tracking  dye  had  migrated  0.5  cm.  After  trypsin  digestion,  these  
samples  were  used  to  analyze  all  components  isolated  using  the  IP  experiments.  The  
gel  on  the  right  was  separated  2cm,  and  regions  of  the  cross-­linked  samples  that  
corresponded  to  AE1  monomers,  dimers,  and  tetramers  (indicated  by  red  arrows  and  
text)  were  excised,  digested  with  trypsin,  and  analyzed  by  LC-­MS/MS.  
  
Upon  completing  the  analysis  of  the  AE1  IP  samples,  I  saw  that  the  majority  of  
AE1  cross-­links  involving  the  N-­terminal  domain  and  the  C-­terminal  domain  were  
present  in  all  3  samples  corresponding  to  putative  AE1  bands  (monomer,  dimer,  and  
tetramer),  except  for  cross-­link  group  5,  which  was  only  present  in  tetramers.  A  summary  
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of  the  peptides  found  using  the  combination  of  the  CX-­MS  of  the  25  experiments  
considered  as  part  of  parameter  optimizations  (see  Section  3.3)  and  digests  
corresponding  to  the  7  AE1  IP  experiments,  and  the  cross-­links  found  in  these  32  total  
experiments,  can  be  found  in  Table  4-­1.  Based  on  this  information  and  a  topology  model  
proposed  in  a  previous  study  (Hirai,  Hamasaki  et  al.  2011),  I  was  able  to  develop  an  AE1  
topology  model  (see  Fig.  4-­5)  that  accurately  represented  an  AE1  monomer.  With  this  
model  as  my  guide,  I  could  proceed  with  the  modeling  of  the  full-­length  protein.    




























Cross-­links  Only  Involving  the  AE1  N-­terminal  Domain  
1   32   3,4,5   VYVELQELVMD[E]K   57-­69   HSHAGELELEALGGV[K]PAVLTR  
161-­
180   68   174  




0   174  
3   32   4,5   HSHAGELELEALGGV[K]PAVLTR  
161-­
180   LQEAA[E]LEAVELPVPIR  
247-­
263   174   252  
4   8   4   LQ(E)AA(E)L(E)AVELPVPIR  
247-­




2/254   353  
5   2   4   FLFDLLGP[E]APHIDYTQLGR  
264-­
283   YQSSPA[K]PDSSFYK  
347-­
360   272   353  




384   297   353  
Cross-­links  Involving  the  AE1  N-­terminal  Domain  and  Other  AE1  Cytoplasmic  Segments  
7   8   4   VFT[K]GTVLLDLQETSLAGVANQLLDR  
113-­
138   ATF(DE)EEGR  
893-­
901   116   896/897  









3   743  
9   25  
3,4
,5   FIF(ED)QIR  
139-­




3   826  







757   238   743  
11   28  
3,4
,5   ADFL[E]QPVLGFVR  
234-­
246   YHPDVPYV[K]R  
818-­
827   238   826  
12   19   4  
ADFL[E]QPVLGFVR  
234-­
246   NVELQCLDADDA[K]ATFDEEEGR  
880-­
901   238   892  
13   7   4  
YQSSPA[K]PDSSFYK  
347-­
360   YHP[D]VPYVK  
818-­
826   353   821  
14   32   3,4  
YQSSPA[K]PDSSFYK  
347-­
360   ATFDEE[E]GR  
893-­
901   353   899  
15   25   3   YQSSPA[K]PDSSFYK   347-­ DEY(DE)VAMPV   902-­ 353   905/906  
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360   911  
Cross-­links  Involving  AE1  Cytoplasmic  Segments  
16   7   4  
F[K]NSSYFPGK  
591-­
600   ATF(DEEE)GR  
893-­
901   592  
896/897/8
98/899  
17   30  
3,4
,5   YHPDVPYV[K]R  
818-­
827   ATFD[E]EEGR  
893-­
901   826   897  
18   16   3  
YHPDVPYV[K]R  
818-­
827   DEYD[E]VAMPV  
902-­
911   826   906  
a:  Charge  states  the  cross-­link  group  was  detected  in.  
b  []:  cross-­linked  residue;;  ():  potential  cross-­linked  residue  (ambiguous  location)  
  
Fig.  4-­5:  Alternative  topology  models  for  AE1  relative  to  the  plasma  membrane.  A.  
Topology  model  for  AE1  reported  by  UniProt  (http://www.uniprot.org/uniprot/P02730,  
UniProt  ID  P02730).  B.  Topology  model  for  AE1  as  suggested  by  Hirai,  et  al.,  based  on  
cryo-­EM  data  (Yamaguchi,  Ikeda  et  al.  2010)  and  the  assumption  that  AE1  is  the  result  
of  a  duplication  event  of  a  protein  that  originally  had  six  transmembrane  (TM)  segments  
(Hirai,  Hamasaki  et  al.  2011).  C.  Topology  model  for  AE1  based  on  our  zero-­length  CX-­
MS  data.  The  number  of  amino  acids  in  loops  and  segments  outside  the  lipid  bilayer  are  





Another  important  note  is  that  surprisingly  this  IP  analysis  did  not  result  in  
significant  additional  depth  of  analysis  for  the  AE1  protein.  This  could  be  due  to  the  fact  
that  a  maximum  depth  of  analysis  had  been  achieved  as  part  of  the  optimization  trials  
described  in  Chapter  3;;  that  is,  all  cross-­linked  peptides  in  the  samples  had  been  
identified.  A  more  likely  reason  is  that  ZXMiner  was  designed  to  compare  closely  
matched  control  and  experimental  samples  using  a  label-­free  correlation  of  LC-­MS  
signals.  However,  dimer  and  tetramer  regions  of  IPs  from  cross-­linked  samples  will  not  
completely  match  the  monomer  band  of  AE1  from  IPs  of  control  samples.  These  
inevitable  differences  in  protein  content  have  apparently  impeded  the  ZXMiner  
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software’s  ability  to  identify  cross-­linked  peptides  in  these  simplified  samples  
significantly.    
4.3.3.  Development  of  AE1  transmembrane  model  
I  then  used  Phyre2  to  generate  a  model  of  the  AE1  C-­terminal  domain  described  
in  4.3.2,  using  the  primary  protein  sequence  as  my  input.  Briefly,  Phyre2  generated  a  
model  which  shares  great  protein  fold  similarity  with  the  uracil  transporter  UraA  (Lu,  Li  et  
al.  2011),  which  is  a  protein  that  potentially  shares  some  evolutionary  characteristics  
with  AE1  despite  its  poor  sequence  homology  (see  Fig.  4-­7).  Specifically,  it  is  believed  
that  both  UraA  and  AE1  are  the  result  of  an  internal  duplication  event,  which  is  why  their  
membrane-­bound  domain  architecture  seemingly  consists  of  2  very  similar  sets  of  7  
helices  (see  Fig.  4-­6)  (Hirai,  Hamasaki  et  al.  2011;;  Lu,  Li  et  al.  2011;;  Vastermark  and  
Saier  2014).  
Fig.  4-­6:  Phyre2-­generated  model  for  the  AE1  C-­terminal  domain.  The  PDB  
database  used  to  generate  this  model  is  described  in  Fig.  4-­7.  From  left  to  right:  




Fig.  4-­7:  The  ten  most  relevant  models  from  the  PDB  database  used  by  Phyre2  to  
create  the  AE1  transmembrane  domain  template  structure.  Confidence  and  percent  
sequence  identity  (%i.d.)  scores  are  color-­coded  from  grey  (least)  to  red  (most).  










# Template Alignment Coverage 3D Model Confidence % i.d. Template Information
1 c3qe7A_ Alignment 100.0 15
PDB header:transport protein
Chain: A: PDB Molecule:uracil permease;
PDBTitle: crystal structure of uracil transporter--uraa
2 c1bzkA_ Alignment 99.4 100
PDB header:transport protein
Chain: A: PDB Molecule:protein (band 3 anion transport protein);
PDBTitle: structural studies on the effects of the deletion in the2
red cell anion exchanger (band3, ae1) associated with3 south east
asian ovalocytosis.
3 c1bh7A_ Alignment 96.6 97
PDB header:membrane protein
Chain: A: PDB Molecule:band 3;
PDBTitle: a low energy structure for the final cytoplasmic loop of2
band 3, nmr, minimized average structure
4 c1btrA_ Alignment 90.8 100
PDB header:anion transport
Chain: A: PDB Molecule:band 3 anion transport protein;
PDBTitle: the solution structures of the first and second2
transmembrane-spanning segments of band 3
5 c1btqA_ Alignment 90.8 100
PDB header:anion transport
Chain: A: PDB Molecule:band 3 anion transport protein;
PDBTitle: the solution structures of the first and second2
transmembrane-spanning segments of band 3
6 c1bttA_ Alignment 70.3 100
PDB header:transmembrane protein
Chain: A: PDB Molecule:band 3 anion transport protein;
PDBTitle: the solution structures of the first and second2
transmembrane-spanning segments of band 3
7 c1btsA_ Alignment 68.0 100
PDB header:transmembrane protein
Chain: A: PDB Molecule:band 3 anion transport protein;
PDBTitle: the solution structures of the first and second2
transmembrane-spanning segments of band 3
8 c4us3A_ Alignment 40.7 12
PDB header:transport protein
Chain: A: PDB Molecule:transporter;
PDBTitle: crystal structure of the bacterial nss member mhst in an2
occluded inward-facing state
9 c3b9yA_ Alignment 37.0 13
PDB header:transport protein
Chain: A: PDB Molecule:ammonium transporter family rh-like
protein;
PDBTitle: crystal structure of the nitrosomonas europaea rh protein
10 c4m48A_ Alignment 20.6 10
PDB header:transport protein
Chain: A: PDB Molecule:transporter;
PDBTitle: x-ray structure of dopamine transporter elucidates
antidepressant2 mechanism
11 c4hzuS_ Alignment 18.2 14
PDB header:hydrolase, transport protein
Chain: S: PDB Molecule:predicted membrane protein;




I  then  evaluated  the  AE1  C-­terminal  model  using  the  available  published  
biochemical  data,  as  well  as  the  previously  generated  AE1  topology  model  (see  Fig  4-­5).  
The  topology  model  was  particularly  critical,  as  it  guided  me  in  terms  of  the  number  of  
transmembrane  spans  as  well  as  their  approximate  locations.  The  transmembrane  
spans  in  the  C-­terminal  model  were  counted,  and  the  locations  of  the  sites  for  important  
biochemical  reactions  we  examined.  These  include  sites  such  as  Lys-­542  and  Lys-­851,  
which  react  with  the  H2DIDS  ion  transport  inhibitor  (Okubo,  Kang  et  al.  1994),  the  
complex  oligosaccharide  glycosylation  site  at  Asn-­642,  and  the  palmitoylation  site  at  
Cys-­843  (Mitra,  Ubarretxena-­Belandia  et  al.  2004;;  Li,  Takazaki  et  al.  2006).  Other  key  
residues  used  in  this  evaluation  included  those  involved  in  the  mutation  causing  
Southeast  Asian  ovalocytosis  (residues  400-­408),  the  residues  used  in  previous  studies  
involving  Cys  mutagenesis  scanning  (Gly-­742  and  Ser-­745),  and  the  Lyn  kinase  
phosphorylation  sites  (His-­359  and  His-­904).  
After  performing  all  of  these  analyses,  I  found  that  all  of  these  parameters  were  
in  line  with  expectations.  Therefore,  I  deemed  the  structure  to  be  a  valid  template  for  
combinatorial  modeling  experiments  (see  Section  4.2.4  for  details).  Briefly,  these  
experiments  took  the  AE1  C-­terminal  transmembrane  model  template  and  the  existing  
crystal  structures  of  the  N-­terminal  domain,  and  used  the  cross-­links  determined  in  the  
CX-­MS  analyses  (see  Table  4-­1)  to  constrain  the  location  of  the  cytoplasmic  loops  
between  transmembrane  spans.  These  cross-­links  also  helped  determine  the  position  of  
the  N-­terminal  domain  relative  to  the  C-­terminal  domain,  as  will  be  discussed  below.  
4.3.4.  Validation  and  Analysis  of  Full-­Length  AE1  Structure  
   After  the  final  structure  for  full-­length  AE1  was  determined,  I  validated  it  in  
several  ways.  Firstly,  I  examined  the  distances  between  the  cross-­linked  residues  as  
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described  in  Table  4-­1  to  observe  the  imposed  distance  constraints  for  observed  cross-­
linked  sites.  These  sites  should  result  in  α-­carbon  distances  being  within  12Å  for  cross-­
links  in  well-­ordered  regions  of  the  protein,  or  up  to  16Å  for  disordered  ones.  I  found  that  
all  of  the  cross-­links  examined  were  within  the  expected  distances.  
I  then  interrogated  the  nature  of  the  amino  acid  residues  composing  the  pore  by  
color-­coding  the  residues  according  to  their  hydrostatic  character  and  measured  the  
pore-­spanning  segment  of  the  protein.  This  segment  was  consisted  with  the  expected  
thickness  of  the  membrane  (Mitra,  Ubarretxena-­Belandia  et  al.  2004),  as  shown  in  Fig.  
4-­8a.  This  showed  that  the  transmembrane  spans  were  mostly  composed  of  
hydrophobic  residues,  as  expected.  I  also  examined  the  contact  interface  for  the  AE1  
dimer  within  the  lipid  bilayer.  This  showed  that  the  AE1  C-­terminal  domain  contributes  to  
the  dimerization  interface  in  addi(Eber  and  Lux  2004)tion  to  the  previously  known  
homodimeric  interaction  of  the  cytoplasmic  N-­terminal  domain.  Furthermore,  it  showed  
that  its  contribution  primarily  involves  the  transmembrane  segment  T13  (see  Fig.  4-­8b-­
d).  
Fig.  4-­8.  Full-­length  AE1  dimer  hydrophobicity  and  transmembrane  domain  
dimeric  interface  analysis.  A.  Full-­length  AE1  dimer  (membrane  view).  Hydrophobic  
residues  (Ala,  Gly,  Ile,  Leu,  Met,  Phe,  Pro,  Val)  are  in  gold,  hydrophilic  residues  (Asn,  
Cys,  Gln,  Ser,  Thr,  Trp,  Tyr)  are  in  grey,  positively  charged  residues  (Arg,  His,  Lys)  are  
in  blue,  and  negatively  charged  residues  (Asp,  Glu)  are  in  red.  B.  AE1  transmembrane  
domain  dimeric  interface  (membrane  view).  TM13  (yellow)  and  the  palmitoylated  Cys-­
843  (violet)  form  the  entire  membrane-­embedded  dimer  interface.  C.  AE1  
transmembrane  domain  dimeric  interface  (extracellular  view).  D.  AE1  transmembrane  





Next,  I  examined  the  protein  channel  and  determined  the  arrangement  of  the  
helices  that  comprise  it  (see  Fig.  4-­9a).  From  this  analysis,  I  was  able  to  determine  that  
transmembrane  helices  T1,  T3,  T5,  and  T12  in  AE1  were  playing  a  critical  role  in  the  
formation  of  the  channel  (see  Fig.  4-­9b).  Furthermore,  display  of  the  H2DIDS  site  shows  
that  it  is  present  on  the  extracellular  side  as  previously  determined,  and  importantly,  is  
near  the  helices  that  compose  the  channel.  This  is  in  accordance  with  previously  
performed  mutagenesis  studies  that  determined  that  mutation  of  Lys-­542  and  Lys-­851  
does  not  impede  ion  transport  (Wood,  Muller  et  al.  1992).  These  residues  were  
previously  thought  to  be  loosely  associated  with  the  conformational  changes  the  channel  
undergoes  as  part  of  ion  transport  (Okubo,  Kang  et  al.  1994),  but  not  physically  blocking  
the  channel  opening.  This  is  in  contrast  to  some  of  the  cytoplasmic  loops  on  the  
extracellular  face  of  the  protein,  which  seem  to  be  interfering  with  access  to  the  channel  
entrance.  This  can  be  visualized  by  an  examination  of  Fig.  4-­9c  (which  has  the  loops  
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trimmed  for  clarity)  and  Fig.  4-­9d  (which  displays  the  loops  fully).  Furthermore,  
examining  the  inside  of  the  channel  (see.  Fig.  4-­9e  and  f)  allowed  me  to  estimate  
individual  residues  that  appear  to  contribute  to  the  channel.  Some  of  these  have  already  
been  described  in  the  literature,  most  notably  S465,  which  has  been  shown  to  abolish  
transport  when  mutated  to  a  residue  with  a  large  side  chain,  such  as  Ile,  Asn,  or  Asp  (Li,  
Quilty  et  al.  2000;;  Barneaud-­Rocca,  Etchebest  et  al.  2013;;  Bonar,  Schneider  et  al.  
2013).  
Fig.  4-­9:  The  AE1  channel.  A.  The  AE1  channel  (extracellular  cartoon  view).  
Transmembrane  segments  are  numbered  in  red.  Transmembrane  segments  critical  to  
the  channel  are  colored  in  teal  (TM1),  magenta  (TM3),  brown  (TM5),  and  violet  (TM12).  
H2DIDS  binding  site  residues  are  in  black  sticks.  B.  Simplified  AE1  channel  (extracellular  
sphere  view)  without  extracellular  loops  in  front  of  AE1  channel  site.  C.  AE1  channel  with  
full  extracellular  loops  (extracellular  sphere  view).  D.  AE1  channel  (membrane  cartoon  
view).  E.  AE1  channel  (membrane  book  view).  Potential  key  residues  for  ion  transport  




After  the  channel  was  examined,  I  moved  on  to  the  extracellular  surface  of  the  
AE1  protein.  Here,  I  examined  the  locations  of  the  complex  oligosaccharide  site  at  Asn-­
642  (Li,  Quilty  et  al.  2000;;  Shnitsar,  Li  et  al.  2013),  as  well  as  the  sites  for  previously  
reported  blood  antigens  on  AE1  (Poole  2000)  (see  Fig.  4-­10).  I  found  that  the  most  of  
these  sites  were  correctly  localized  on  the  extracellular  face  beyond  the  projected  
location  of  the  membrane.  The  few  sites  that  were  not  located  on  the  extracelluar  face  
were  loops  with  no  structural  constraints  that  the  modeling  software  could  not  
unambiguously  model.  This  is  due  to  the  fact  that  these  experiments  were  not  conducted  
by  imposing  a  hydrophobic  membrane  restraint  on  residues  located  within  the  lipid  
bilayer,  because  this  is  beyond  MODELLER’s  capabilities.  
Fig.  4-­10:  Analysis  of  AE1  extracellular  region.  A.  AE1  extracellular  sites  (membrane  
cartoon  view).  Hydrophobic  residues  (Ala,  Gly,  Ile,  Leu,  Met,  Phe,  Pro,  Val)  are  in  gold,  
hydrophilic  residues  (Asn,  Cys,  Gln,  Ser,  Thr,  Trp,  Tyr)  are  in  grey,  positively  charged  
residues  (Arg,  His,  Lys)  are  in  blue,  negatively  charged  residues  (Asp,  Glu)  are  in  red,  
blood  antigen  sites  are  in  teal  sticks,  H2DIDS  binding  site  residues  are  in  black  sticks,  
and  complex  oligosaccharide  site  (Asn-­642)  is  in  orange  sticks.  B.  AE1  extracellular  




The  next  step  was  to  examine  the  cytoplasmic  face  of  AE1  in  order  to  
comprehensively  evaluate  the  3D  arrangement  of  the  N-­terminal  domain  in  relation  to  
the  channel,  as  well  as  to  the  other  cytoplasmic  loops.  In  order  to  do  so,  I  color-­coded  
the  C-­terminal  domain’s  cytoplasmic  loops  using  the  color  scheme  as  shown  in  the  
topology  model  (see  Fig.  4-­5).  I  then  analyzed  the  3D  arrangement  of  these  multiple  
cytoplasmic  segments  (see  Fig.  4-­11),  and  I  saw  extensive  interaction  between  the  C-­
terminal  domain’s  cytoplasmic  loops  and  the  N-­terminal  domain.  Of  particular  note  is  that  
residues  806-­835  (in  red)  are  clearly  shown  as  cytoplasmic  in  localization.  This  is  
interesting,  as  prior  publications  reached  conflicting  conclusions  regarding  whether  this  
loop  is  cytoplasmic  (Erickson  1997;;  Popov,  Li  et  al.  1999)  or  extracellular  (Popov,  Tam  
et  al.  1997),  and  it  has  been  suggested  that  its  conformation  can  change  in  response  to  
stimuli  (Jin,  Abe  et  al.  2003).  The  extreme  C-­terminal  portion  of  AE1  (residues  877-­911,  
in  blue)  also  seems  to  be  contributing  to  the  dimerization  interface,  which  was  not  
previously  known.  These  insights  combine  to  indicate  that  the  homodimer  interface  is  
much  more  extensive  than  previously  known.  
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Fig.  4-­11:  Cytoplasm-­membrane  interface  of  an  AE1  dimer.  A.  The  N-­terminal  
domain  (yellow  and  wheat)  and  cytoplasmic  loops  (membrane  cartoon  view).  
Cytoplasmic  loops  are  colored  using  the  color  scheme  previously  shown  in  Fig.  4-­5.  B.  
Surfaces  views  of  the  structure  shown  in  A.  
  
Next,  I  decided  to  examine  the  channel’s  exit  location  in  relation  to  the  N-­
terminus,  as  well  as  examine  several  important  reaction  sites  on  AE1.  These  include  the  
Lyn  kinase  phosphorylation  sites  on  Tyr-­359  and  Tyr-­904  (Brunati,  Bordin  et  al.  2000),  
as  well  as  the  DEPC  inhibitor  site  on  His-­834  (Jin,  Abe  et  al.  2003),  and  the  location  of  
the  Southeast  Asian  ovalocytosis  deletion  mutant  (residues  400-­408)  (Barneaud-­Rocca,  
Borgese  et  al.  2011).  This  analysis  showed  that  AE1’s  channel  exit  site  seems  to  be  
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angled  away  from  where  the  N-­domain  region  lies,  and  is  instead  pointed  toward  the  
dimeric  interface  (see  Fig.  4-­12).  This  is  consistent  with  a  previous  study  that  examined  
the  N-­terminal  domain  of  AE1  to  determine  whether  it  had  a  substrate  access  tunnel  to  
pass  ions  through  into  the  cytoplasm,  and  did  not  find  one  (Shnitsar,  Li  et  al.  2013).  We  
also  observe  that  both  the  phosphorylation  sites  and  the  DEPC  binding  site  in  our  model  
are  near  to  the  proposed  channel  exit,  which  is  consistent  with  their  roles  in  ion  transport  
inhibition  (Jin,  Abe  et  al.  2003).  The  Southeast  Asian  ovaloctyosis  deletion  mutant  site  is  
on  opposite  face  of  the  molecule  from  the  proposed  channel  exit  site,  which  superficially  
could  suggest  that  there  is  no  association  between  this  region  and  ion  transport.  
However,  our  model  shows  that  these  residues  that  are  probably  quite  important  for  
protein  folding,  because  they  are  part  of  the  membrane-­entry  portion  of  the  TM1  
transmembrane  segment.  Thus,  the  deleterious  effects  observed  in  this  deletion  mutant  
(Tanner  2002;;  Yusoff,  Van  Rostenberghe  et  al.  2003;;  Barneaud-­Rocca,  Borgese  et  al.  
2011)  could  be  due  to  channel  misfolding.  
Fig.  4-­12:  Arrangement  of  AE1  cytoplasmic  loops  and  binding  sites  relative  to  the  
ion  channel  exit  site.  A.  AE1  cytoplasmic  loops  and  proposed  channel  exit  site  
(membrane  cartoon  view).  Cytoplasmic  loops  are  as  shown  in  Fig.  4-­5,  and  AE1  channel  
helices  are  colored  as  shown  in  Fig.  4-­8.  Furthermore,  Lyn  kinase  phosphorylation  sites  
(Tyr-­359  and  Tyr-­904)  are  shown  in  white  sticks,  the  DEPC  inhibitor  binding  site  is  in  teal  
sticks,  and  the  Southeast  Asian  ovalocytosis  mutation  site  (400-­408)  is  shown  in  black  
sticks.  The  proposed  channel  exit  site  is  shown  as  a  black  arrow.  B.  A  sphere  view  of  the  
image  in  panel  A,  except  the  proposed  channel  exit  site  is  highlighted  with  a  white  arrow  





   In  summary,  I  was  able  to  take  zero-­length  CX-­MS  data  derived  from  an  
optimized  method  for  the  QE+  instrument  on  a  complex  WG  sample  and  generate  cross-­
link  identifications  for  the  AE1  protein.  I  then  took  these  cross-­links  and  combined  them  
with  previously  reported  crystal  structures  and  biochemical  data  in  order  to  form  an  
experimentally  validated  model.  While  this  model  has  some  limitations  due  to  the  nature  
of  the  cross-­link  localization  and  the  nature  of  the  modeling  experiments  themselves,  I  
believe  it  provides  a  reasonable  picture  of  the  structure  and  properties  of  this  important  
erythrocyte  membrane  protein.  
   However,  while  preparing  this  thesis  document,  I  became  aware  of  an  accepted  
publication  involving  a  crystal  structure  of  AE1’s  C-­terminal  domain  [Arakawa,  T.,  et  al.;;  
Structure  of  the  anion  exchanger  domain  of  human  erythrocyte  Band  3;;  manuscript  
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accepted],  that  was  accepted  in  late  September  2015.  Based  on  a  review  of  a  copy  of  
the  accepted  manuscript,  the  crystal  structure  is  generally  similar  to  my  AE1  C-­terminal  
domain  model.  However,  it  also  contains  some  differences  in  important  details  compared  
to  that  model.  I  unfortunately  have  not  yet  been  able  to  access  the  PDB  data  for  this  
structure  in  order  to  perform  a  more  detailed  comparison  between  the  two  structures.  
However,  based  on  review  of  the  manuscript,  I  can  make  several  preliminary  
observations.  First  among  these  is  that  both  structures  have  14  transmembrane  
segments  in  their  respective  C-­terminal  domains.  Secondly,  both  structures  used  UraA  
as  a  template  for  the  C-­terminal  domain  architecture.  Some  of  the  major  differences  
center  around  the  architecture  of  the  channel  –  the  crystal  structure’s  channel  is  
composed  of  TM1-­TM4  and  TM8-­TM11,  whereas  my  model’s  channel  identified  the  key  
transmembrane  segments  to  be  TM1,  TM3,  TM5,  and  TM12.  On  the  other  hand,  several  
cytoplasmic  loops  that  I  have  identified  cross-­links  for  (most  notably  742-­753)  are  poorly  
resolved  in  the  crystal  structure,  and  the  crystal  structure  does  not  correlate  the  C-­
terminal  domain  with  the  N-­terminal  domain.  
   When  the  PDB  file  is  publically  released,  I  plan  to  compare  my  structure  to  the  
crystal  structure  in  precise  detail.  I  will  also  perform  new  modeling  experiments  using  the  
crystal  structure  as  a  template  to  obtain  a  structure  of  the  entire  AE1  protein.  I  expect  
this  final  structure  to  be  highly  accurate,  given  that  I  will  have  multiple  crystal  structure  
templates  coupled  with  a  good  density  of  zero-­length  cross-­link  identifications  between  
the  N-­terminal  domain  and  the  cytoplasmic  segments  of  the  C-­terminal  domain.  This  
includes  several  segments  that  do  not  seem  to  be  present  in  the  crystal  structure  of  the  
C-­terminal  domain.  The  combined  structure  will  yield  the  most  definitive  insights  on  full-­
length  AE1’s  structure  and  function  to  date.  
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Chapter  5:  Future  directions  
5.1.  Further  improvements  in  the  density  of  identification  zero-­length  cross-­links  
5.1.1.  CX-­MS  analysis  method  improvements  
One  of  the  most  critical  future  directions  is  further  development  of  the  zero-­length  
CX-­MS  technique.  Maximizing  extent  of  cross-­linking  combined  with  improved  depth  of  
analysis  results  should  both  improve  the  confidence  of  assigned  cross-­link  site  
identifications  and  increase  the  density  of  the  resulting  distance  constraints  to  improve  
the  accuracy  of  molecular  modeling.  This  can  be  approached  in  several  ways,  which  I  
will  describe  in  detail  below.  
One  way  to  optimize  peptide  identification  lies  with  improving  the  software’s  
detection  methodology.  In  addition  to  the  collaborative  methodology  used  to  account  for  
the  presence  of  the  precursor  ion  in  QE+  MS/MS  spectra  described  in  Chapter  3,  I  have  
also  discussed  some  problems  with  in  the  peak  deisotoping  algorithm  with  Dr.  Sriswasdi,  
which  results  in  peaks  being  assigned  a  mass  that  is  ±1  Da  (nominally)  off  from  their  
actual  mass,  thus  bringing  down  the  GM  scores  for  these  IDs.  Dr.  Sriswasdi  is  currently  
working  on  software  improvements  in  order  to  address  this  problem.  
Perhaps  the  most  productive  avenue  of  potential  optimization  is  to  further  adapt  
the  protocol  to  higher-­throughput  instruments.  The  Speicher  lab  has  recently  acquired  a  
Thermo  Q  Exactive  HF  instrument  (referred  to  hereafter  as  QE-­HF),  which  offers  
increased  speed  of  MS/MS  data  acquisition  when  compared  to  the  QE+,  and  is  
otherwise  quite  similar.  Testing  and  analysis  of  zero-­length  CX-­MS  data  on  the  QE-­HF  
should  be  further  explored.  
97  
  
Finally,  CX-­MS  sample  preparation  can  be  optimized.  While  options  with  regards  
to  traditional  sample  purification  are  limited  (as  described  in  Chapter  1),  the  
immunoprecipitation  (IP)  experiments  that  were  described  in  Chapter  4.2.2  could  be  
employed  in  the  case  where  an  analyte  of  interest  has  been  previously  identified.  This  
could  help  reduce  sample  complexity  and  thus  lead  to  further  depth  of  analysis.  One  
precaution  that  has  to  be  taken  when  using  this  approach  is  that  ZXMiner’s  (Sriswasdi,  
Harper  et  al.  2014)  label-­free  comparison  module  was  designed  with  the  assumption  that  
the  uncross-­linked  control  sample  was  identical  to  the  experimental  cross-­linked  sample  
with  the  exception  of  the  introduction  of  a  moderate  number  of  cross-­links,  but  this  will  
not  be  the  case  with  IP  samples.  This  is  most  likely  the  reason  why  the  IP  samples  for  
AE1  did  not  significantly  increase  depth  of  analysis,  as  was  discussed  in  Section  4.3.2.  
Because  of  this  limitation,  it  is  possible  that  the  improvements  made  using  this  approach  
will  be  more  modest  than  the  other  two.  
5.1.2.  Potential  side  reactions  and  their  potential  interference  in  cross-­linked  
peptide  identification  
   A  potential  issue  that  may  need  to  be  addressed  in  the  preparation  of  zero-­length  
CX-­MS  samples  is  the  possibility  of  side  reactions.  Although  the  original  paper  that  
described  the  EDC/NHS  cross-­linking  protocol  did  not  report  any  side  reactions  
(Grabarek  and  Gergely  1990),  some  studies  have  reported  seeing  EDC  adducts  at  high  
cross-­linker  concentrations  (Bruce  2012).  In  order  to  test  for  side  reactions,  I  have  
performed  intact  LC-­MS  analysis  of  intact  proteins  that  were  cross-­linked  using  
EDC/NHS  chemistry  on  a  LTQ  Orbitrap-­XL  with  a  trap-­column-­only  UPLC  setup  in  30-­
minute  time  intervals.  These  experiments  detected  multiple  mass  modifications  of  
unknown  origins,  as  they  did  not  correspond  to  the  expected  mass  shifts  for  the  reported  
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cross-­linking  intermediates  for  the  EDC  carbodiimide  and  the  NHS-­ester  intermediate.  
These  unknown  intermediates  were  also  detected  by  surveying  modifications  to  linear  
peptides  in  MaxQuant  using  the  dependent  peptide  function  (Cox  and  Mann  2008).  This  
function  uses  the  previously  identified  peptides  found  in  a  database  search  as  the  
forward  database  for  a  second  dataset  search,  which  only  involves  unidentified  peptides.  
This  second  database  search  looks  for  mass  differences  between  identified  peptides  
and  unidentified  peptides  with  similar  MS/MS  peak  patterns,  and  scores  the  hits  based  
on  the  similarity  of  their  MS/MS  spectra.  These  peptide  hits  and  corresponding  mass  
differences  are  then  reported,  and  matched  to  a  mass  shift  database  whenever  possible.  
In  the  case  of  the  EDC/NHS  mass  modifications,  the  precise  chemical  composition  of  
these  intermediates  remains  unknown.  Further  studies  to  characterize  the  nature  of  
potential  intermediates  and  their  approximate  yields  relative  to  cross-­linked  peptides  are  
needed  in  order  to  incorporate  these  side  reaction  products  into  the  data  analysis  
pipeline.  
5.1.3.  Alternative  cross-­linkers  
Another  potential  direction  this  research  project  could  explore  is  the  use  of  
alternative  cross-­linkers.  In  addition  to  testing  one  of  the  more  established  cross-­linkers  
described  in  Chapter  1,  I  am  also  interested  in  testing  a  recently  published  acidic-­
residue-­specific  cross-­linker  from  the  Aebersold  lab  called  DMTMM  (Leitner,  Joachimiak  
et  al.  2014).  This  cross-­linker  has  been  reported  to  produce  zero-­length  cross-­links  as  
well  as  cross-­links  with  spacer  arms  of  various  lengths,  so  the  ensuing  cross-­linking  
chemistry  has  to  be  further  tested  and  clarified.  If  a  consistent  reaction  product  can  be  
obtained  with  this  reaction,  it  could  be  used  as  a  complement  to  EDC/NHS  cross-­linking.  
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It  could  even  be  used  as  a  potential  replacement  if  the  zero-­length  cross-­linking  activity  
can  be  isolated  and  is  superior  in  terms  of  depth  of  analysis.  
5.1.4.  Incorporation  of  tandem  mass  tags  (TMT)  
   Another  potential  alternative  approach  for  the  identification  of  zero-­length  CX-­MS  
products  is  to  employ  tandem  mass  tags  (TMT)  in  order  to  aid  in  their  identification.  
These  tags  could  be  applied  to  cross-­linked  samples  during  sample  preparation  in  order  
to  facilitate  sample  preparation,  as  well  as  potentially  reduce  MS  time  by  requiring  less  
samples  in  order  to  achieve  the  requisite  depth  of  analysis  to  successfully  ID  enough  
peptides  to  inform  modeling  experiments.  The  reason  why  such  a  method  would  require  
less  samples  per  LC-­MS  analysis  is  because  a  set  of  TMT  tags  would  allow  a  number  of  
samples  equal  to  the  number  of  tags  in  the  set  (for  example,  6  separate  isobaric  tags  in  
a  TMT  6-­plex)  to  be  pooled  into  a  single  MS  run.  This  single  MS  run  would  also  not  need  
an  uncross-­linked  control  sample,  as  our  current  zero-­length  CX-­MS  method  does.  This  
lack  of  a  control  sample  could  prove  useful  in  terms  of  reducing  the  amount  of  protein  
required  to  perform  an  LC-­MS  analysis,  as  well  as  eliminate  some  of  the  previously  
reported  limitations  for  IP  experiments.  
5.2.  Improvements  to  modeling  method  using  zero-­length  CX-­MS  distance  
constraints  
5.2.1.  Alternative  modeling  approaches  
   Yet  another  option  to  potentially  improve  the  CX-­MS  method  is  to  reconsider  the  
modeling  software  used  to  apply  the  CX-­MS  restraints.  As  I  alluded  to  earlier,  
MODELLER  (Sali  and  Blundell  1993)  is  a  homology  modeling  program,  and  thus  needs  
template  structures  in  order  to  provide  3D  representations  of  a  given  system.  In  order  to  
ensure  maximum  fidelity  and  accuracy  to  the  original  structure,  I  strongly  prefer  to  use  
100  
  
structural  information  corresponding  to  the  protein  itself.  Alternatively,  I  could  also  use  a  
protein  that  has  demonstrated  sequence  or  structural  homology  in  order  to  make  a  
template,  as  I  did  for  AE1  (see  Chapter  4.2.3).  However,  structural  information  of  this  
kind  is  not  always  available.  I  have  also  found  that  MODELLER  is  somewhat  limited  
when  faced  with  regions  that  are  poorly  constrained.  Two  examples  of  poorly  
constrained  regions  are  cytoplasmic  loops  with  no  identified  cross-­links,  and  large  
protein  complexes  whose  binding  interface  between  components  is  relatively  small.  In  
the  event  that  the  cross-­linking  data  or  the  available  template  structures  are  not  sufficient  
to  ensure  a  high  degree  of  confidence  from  a  MODELLER  run,  a  program  like  the  
Rosetta  software  suite  (Simons,  Bonneau  et  al.  1999)  could  be  used  to  try  and  
accomplish  these  tasks.  
5.2.2.  Importance  of  cross-­link  density  in  homology  modeling  experiments  
   One  of  the  reasons  why  I  am  considering  alternative  modeling  approaches  in  the  
previous  section  is  because  my  CX-­MS  supported  homology  modeling  experiments,  
particularly  the  AE1  project  discussed  in  Chapter  4,  have  enhanced  my  awareness  of  
the  technique’s  inherent  limitations.  These  limitations  are  mainly  that  either  a  certain  
degree  of  cross-­link  density  is  required  to  have  a  high  degree  of  confidence  in  the  
modeling  of  a  given  region,  or  a  strongly  defined  homologous  template  structure  is  
needed  for  that  region.  Without  either  of  these  constraints,  some  regions  in  modeling  
experiments  are  only  subject  to  the  modeling  software’s  energy  minimization  function,  
which  does  not  necessarily  reflect  the  biologically  relevant  structure  of  the  protein  or  
protein  complex.  
The  above  limitations  became  readily  apparent  during  the  AE1  project  discussed  
in  Chapter  4.  As  was  mentioned  in  Section  4.4,  I  was  recently  provided  an  advance  copy  
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of  a  manuscript  accepted  in  Science  [Arakawa,  T.,  et  al.;;  Structure  of  the  anion  
exchanger  domain  of  human  erythrocyte  Band  3;;  manuscript  accepted],  which  described  
a  crystal  structure  of  the  AE1  C-­terminal  domain.  While  I  do  not  have  access  to  the  PDB  
file,  I  was  able  to  make  some  preliminary  comparisons  between  the  structure  of  the  C-­
terminal  domain  in  my  full-­length  AE1  model  and  the  crystal  structure.  
These  comparisons  have  shown  me  that  some  aspects  of  my  analysis  were  
correct.  These  include  the  number  of  transmembrane  spans  in  the  AE1  C-­terminal  
domain,  the  general  residue  ranges  and  hydrophobic  nature  of  these  spans,  and  the  
structural  homology  between  AE1  and  UraA  despite  their  poor  sequence  similarity.  
However,  other  aspects  differed  significantly  from  the  crystal  structure.  Foremost  among  
these  differences  is  the  nature  of  the  helices  that  compose  the  channel  region  and  its  
critical  residues.  Unfortunately,  because  of  the  soluble  nature  of  the  EDC  cross-­linking  
reagent,  I  was  not  able  to  obtain  any  cross-­links  within  the  lipid  bilayer.  Similarly,  I  did  
not  detect  any  cross-­links  between  extracellular  loops,  which  could  be  due  to  the  fact  
that  the  EDC  cross-­linker  is  not  membrane-­permeable  because  of  its  anionic  charge.  
This  lack  of  distance  constraints  did  not  allow  me  to  fully  refine  the  transmembrane  
segments  in  order  to  come  up  with  an  accurate  structure.  This  shows  that  further  
modeling  attempts  using  the  current  protocol  should  have  either  better  high-­confidence  
template  structures  or  have  a  some  cross-­linked  peptides  across  all  major  areas  of  the  
protein,  in  order  to  ensure  maximum  accuracy.  When  the  PDB  file  of  the  crystal  structure  
for  the  C-­terminal  domain  of  AE1  becomes  available,  I  will  incorporate  it  into  my  full-­
length  AE1  model.  I  will  revise  my  structure  of  the  full-­length  AE1  protein  and  any  
functional  interpretations  made  accordingly.  
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5.3.  Further  CX-­MS  analysis  of  human  erythrocyte  membranes  
   Another  future  direction  for  the  zero-­length  CX-­MS  project  is  to  both  further  mine  
existing  datasets  of  cross-­linked  White  Ghosts  (WG)  and  conduct  new  cross-­linking  
experiments.  Although  Chapter  4  of  this  document  focused  extensively  on  AE1,  there  
are  several  other  major  protein  components  in  the  erythrocyte  membrane  that  were  
represented  in  the  cross-­linked  peptide  datasets.  These  included  large  oligomeric  
proteins  such  as  ankyrin  and  spectrin,  as  well  as  actin,  and  tropomyosin,  protein  4.1,  
protein  4.2,  glycophorin-­A,  α-­adducin,  and  β-­adducin.  If  optimum  depth  of  analysis  for  
CX-­MS  on  WG  samples  is  achieved,  there  could  be  enough  cross-­link  identifications  to  
begin  building  structures  of  the  individual  components  that  are  poorly  characterized.  
Alternatively,  a  cross-­link  interface  between  two  or  more  unique  components  of  the  
erythrocyte  membrane  that  already  have  partial  or  full  structural  information  available  
could  be  pursued.  This  would  lead  to  the  generation  of  an  experimentally  validated  
model  of  one  of  the  membrane’s  major  protein  complexes,  such  as  the  ankyrin-­spectrin  
complex  with  AE1  or  the  actin  junctional  complex  (see  Fig.  4-­1).  I  believe  that  both  
approaches  have  merit,  given  that  I  detected  and  identified  cross-­links  for  many  of  these  
proteins  as  part  of  the  studies  involving  AE1.  Unfortunately,  I  was  not  able  to  gather  
enough  information  to  comprehensively  elucidate  new  structures  of  individual  proteins  or  
protein  complexes.  However,  I  believe  that  the  water-­soluble  nature  of  the  majority  of  
these  proteins  make  it  very  feasible  to  achieve  the  requisite  depth  of  analysis  needed  
interrogate  them  further.  
5.4.  Summary  
   In  conclusion,  I  believe  that  there  are  several  methods  that  can  be  further  
optimized  in  order  to  improve  the  CX-­MS  method.  Specifically,  ways  to  improve  the  
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sample  preparation,  data  acquisition,  and  data  analysis  protocols  have  all  been  
described.  Moreover,  analysis  of  the  proteins  and  protein  complexes  that  interact  with  
AE1  remain  under-­characterized.  This  could  be  a  very  promising  opportunity  for  
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